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The auditory system 
 
The human ear consists of three parts: the external ear, the middle ear and the 
inner ear (Figure 1). The external ear comprises the pinna and the external 
auditory ear canal. The tympanic membrane at the end of the external auditory 
canal delineates the beginning of the middle ear. When sound waves travel 
down the ear canal, they cause the tympanic membrane to vibrate which, in 
turn, cause the ossicular chain in the middle ear to move. The ossicular chain 
contains the malleus, the incus and the stapes. The stapes is in connection with 
the oval window and as the stapes footplate moves in the oval window, sound 
vibrations are passed to the cochlea (Figure 1). 
 
 
 
 
 
 
 
 
 
1. Pinna 
2. External auditory ear canal 
3. Tympanic membrane 
4. Malleus 
5. Incus 
6. Stapes 
7. Cochlea 
                         external ear                            middle ear    inner ear 
                                                            
 
Figure 1. Anatomy of the ear. Source: Cochlear Benelux. 
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The cochlea is subdivided into three spiral compartments: the scala tympani, 
the scala vestibuli and the scala media. These compartments are filled with 
lymphatic fluid. The scala media lies between the scala tympani and scala 
vestibuli and contains the organ of Corti, resting on the basilar membrane 
(Figure 2). When sound vibrations are transmitted to the cochlea, the lymphatic 
fluid in the cochlear scalae is set in motion and the longitudinal wave causes 
movement of the basilar membrane. As a consequence of this movement of the 
basilar membrane, the sensory haircells in the organ of Corti are activated and 
evoke action potentials. These action potentials stimulate the cochlear nerve. 
Damage to any of the structures in the external ear, middle ear or inner ear can 
lead to hearing loss. 
 
 
                      
 
 
 
                     1. Scala vestibuli 
                     2. Scala media 
                     3. Organ of Corti 
                     4. Basilar membrane 
                     5. Scala tympani 
                     6. Cochlear nerve 
 
 
 
 
 
Figure 2. Cross section of one loop of the cochlea, including the organ of Corti.  
Source: www.cognet.mit.edu. 
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Types of hearing loss 
 
Hearing loss can be divided into three types: conductive hearing loss, 
sensorineural hearing loss and a combination of conductive and sensorineural 
hearing loss, called mixed hearing loss. This classification is based on the 
affected part of the hearing organ.  
Conductive hearing loss is caused by a disorder of the external ear (e.g. 
impacted wax, atresia of the external ear canal, external otitis or a perforated 
eardrum), a disorder of the middle ear (e.g. luxation of the ossicular chain, 
otosclerosis, cholesteatoma or, in case of otitis media with effusion, the 
presence of fluid) or a disorder of both the external and middle ear. With 
conductive hearing loss, sounds are not well transmitted to the unaffected, 
normal functioning inner ear. 
Sensorineural hearing loss is caused by a disorder restricted to the inner ear, 
the cochlear nerve or both the inner ear and cochlear nerve. Sensorineural 
hearing loss can be due to a congenital disorder (e.g. genetic defect or inner 
ear anomaly), an acquired disorder (e.g. infection, neoplasm or trauma) or an 
autoimmune inner ear disease. Presbyacusis, or age-related hearing loss, is an 
example of sensorineural hearing loss where the loss is predominantly restricted 
to high frequency sounds. 
 
Semi-implantable hearing aids 
 
Hearing loss is a prevalent health condition, affecting approximately 1.5 million 
people in the Netherlands1. The prevalence of hearing loss increases with age. 
In the Netherlands, indication for hearing aid fitting is when the hearing loss is 
35 dB HL or higher. However, approximately 30% of the patients who could 
benefit from amplification do not seek assistance from hearing aids1. 
Furthermore, of the patients who purchase conventional hearing aids, 
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approximately 16% do not wear their devices2 due to shortcomings of 
conventional hearing aids, such as unsatisfactory sound quality due to limited 
frequency range and undesired distortion, occlusion of the outer ear canal, and 
acoustic feedback with high amplification. The introduction of digital signal 
processing in acoustic hearing aids in the late nineteen nineties, has led to 
wider acceptance, owing to improved sound quality and comfort. Nevertheless, 
these devices still have limitations in certain patients. Finally, conventional 
acoustic hearing aids are not popular because of their association with social 
stigma, such as being old or handicapped. Over the past few years, hearing aids 
are being developed that are smaller and designed for esthetics. 
In addition, medical conditions might prevent the fitting of hearing aids like in 
chronic external otitis. Use of hearing aids might be contraindicated because 
the ear mold that occludes the external ear canal might worsen the external 
otitis. Today, there is the possibility of fitting special ear molds, the so-called 
open ear mold fitting. However, this is not a sufficient option to prevent 
external otitis in every patient. In patients with moderate to severe hearing 
loss, the ear molds of the hearing aids can also cause acoustical problems. 
Occlusion of the ear canal might lead to complaints about the patient’s own 
voice and it will block any residual hearing (e.g. in the low frequencies if the 
patient has only high-frequency hearing loss). Another limitation is obtained 
when the hearing loss is profound; acoustic hearing aids may only support lip-
reading. 
Besides improvement in acoustic devices, such drawbacks of conventional 
acoustic hearing aids have also led to the development of (semi-) implantable 
hearing aids. Three different types of implantable hearing aids can be 
distinguished: (1) cochlear implants, which stimulate the acoustic nerve directly 
by means of electrodes positioned in the cochlea; (2) middle ear implants with 
a transducer that directly drives one of the middle ear ossicles or one of the 
cochlear windows; and (3) direct bone-conduction devices, which transfer sound 
signals via bone-conduction directly to the cochlea. These hearing devices have 
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different areas of application and each semi-implantable hearing aid is 
discussed below. A subdivision is made into devices for patients with 
sensorineural hearing loss and devices for patients with conductive or mixed 
hearing loss.  
 
Semi-implantable hearing devices for patients with sensorineural hearing 
loss  
 
Cochlear implants (CIs) 
CIs have been developed for individuals with severe-to-profound sensorineural 
hearing impairment or for individuals with total deafness and a good 
functioning cochlear nerve and who do not benefit from acoustic devices. A CI 
can be divided into an external and an internal part. The external part contains 
the microphone, the audio processor and the transmitter, whereas the internal 
part of the device contains the receiver and the electrode array (Figure 3). The 
microphone is usually part of the audio processor, fitted behind the ear, and 
registers sounds from environment. The audio processor converts the sounds to 
encoded signals, which are transmitted by a coil through the skin by means of 
electromagnetic induction. These signals are picked up by the internal part just 
beneath the skin and transferred to electrodes placed inside the cochlea in the 
scala tympani. The electrodes directly stimulate the cochlear nerve dendrites 
resulting in action potentials that are transmitted through the auditory 
pathways to the brain. 
The first CI for clinical purposes was developed in the late 1960s by the House 
Ear Institute in Los Angeles, California3. It was a single-channel CI, in which 
the entire speech signal was delivered to one electrode. With a single-channel 
system it was not possible to transfer the spectral information of speech. 
Multiple-channel systems were later developed and remain the current standard.  
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       1. Audio processor with microphone 
       2. Transmitter 
       3. Receiver 
       4. Intracochlear electrode array 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A cochlear implant. Source: Cochlear Benelux. 
 
Middle ear implants (MEIs) 
Implantable middle ear devices are available in two types: piezoelectric and 
electromagnetic. The first MEI system on the market was a piezoelectric MEI, 
developed by Suzuki, Yanaghari and co-workers4 and was clinically introduced in 
1984. It was designed for use by patients with conductive or mixed hearing loss 
with a limited sensorineural component. As the piezoelectric transducer had to 
be coupled directly to the head of the stapes, the stapes had to be 
disconnected from the incus to fit the transducer. This first MEI had limited 
ability to compensate for the sensorineural hearing loss component of the 
hearing loss5.  
Subsequent MEIs had an electromagnetic transducer. The Vibrant Soundbridge 
(VSB) (Med-El, Innsbruck, Austria) was the first FDA-approved electromagnetic 
semi-implantable MEI and was originally intended for use by individuals with 
moderate-to-severe sensorineural hearing loss with normal middle ear anatomy 
who had been unsuccessful with conventional hearing aids6.  
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The VSB has been on the market since mid-1990 and it is now the most 
frequently used MEI. It is composed of an external and an internal part that 
communicate with each other by transcutaneous electro-magnetic conduction 
(Figure 4). The external part contains an audio processor with microphone, 
electronics and a transmitter; the internal part contains a receiver unit, which 
is connected to an output transducer, called floating mass transducer (FMT). 
The FMT comprises a coil and magnet, mounted together in a cylinder. When an 
alternating current is applied, the magnet moves and the cylinder vibrates in 
the opposite direction. The FMT is surgically attached to the long process of the 
incus so it vibrates in parallel with the stapes6.  
 
 
 
 
 
 
 
1. Audio processor with     
    microphone 
2.   Receiver 
3. Floating Mass  
     Transducer (FMT) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The Vibrant Soundbridge. Source: Med-El. 
 
Another commercially available electromagnetic semi-implantable MEI, the 
Otologics Middle Ear Transducer (MET) (Otologics Company, Boulder, Colorado, 
USA), was introduced in the late 1990s. Like the VSB, it was developed for 
individuals with moderate-to-severe sensorineural hearing loss. Compared to the 
VSB, the Otologics MET is more powerful and is therefore more suitable for 
patients with severe sensorineural hearing loss7. The electromagnetic transducer 
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of the Otologics MET is attached to the incus by means of a connecting rod 
(Figure 5). The tip of the moving rod is placed in a small hole, made by laser, in 
the body of the incus. The transducer is anchored in the surgically enlarged 
mastoid. The audio processor and microphone form the external part. Sounds 
are transmitted, via the receiver just beneath the skin, from the audio processor 
to the transducer. Mechanical vibration of the probe tip of the transducer 
effects in a vibration of the ossicular chain and thus causes the perception of 
amplified sound.  
 
 
 
 
 
 
 
 
                        
 
 
        1. Audio processor with microphone 
                       2. Receiver 
                       3. Transducer     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The Otologics Middle Ear Transducer. Source: Otologics. 
 
Semi-implantable hearing devices for patients with conductive or mixed 
hearing loss  
 
Bone conduction devices (BCDs) 
Bone conduction hearing is a result of sound being passed through to the bone 
of the skull, e.g. by a vibrator placed behind the ear. These vibrations are 
transmitted with relatively low attenuation. Therefore, the bony cochlear shell 
will vibrate, which causes the fluids in the cochlea to vibrate. The inertia of the 
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inner ear fluids will result in longitudinal fluid waves from one cochlear window 
to the other and causes the basilar membrane to vibrate. In addition to this 
mechanism of cochlear stimulation, there are several other mechanisms 
described by Tonndorf8. 
A conventional BCD comprises a behind-the-ear bone conduction transducer 
that is held in place by means of a steal band over the head or the transducer is 
mounted in a spectacle frame. This transducer is pressed against the skull in the 
mastoid area to transmit transcutaneous sounds (indirectly) to the skull. For 
good speech recognition results, the transducer requires constant pressure 
against the skull to minimize sound loss in the soft tissues of the external 
mastoid. This pressure can cause various complaints, such as local pain, 
headache and skin irritation. 
An alternative for the conventional BCD is the implantable, or percutaneous, 
(direct) BCD. The first-known implantable BCD is the Bone-Anchored Hearing 
Aid (Baha; Cochlear Bone Anchored Solutions AB, Göteborg, Sweden). The Baha 
was developed by Håkansson and Tjellström9. It is a semi-implantable 
percutaneous bone conduction hearing device secured to the skull behind the 
auricle by an osseo-integrated titanium fixture (Figure 6). A percutaneous 
titanium abutment is connected to the fixture and an audio processor can be 
attached to it. The microphone contained in the audio processor picks up 
sounds, amplifies the sounds and transfers them to the cochlea by bone 
conduction via the skull. Percutaneous BCDs were initially indicated for patients 
with a conductive or mixed hearing loss who could not be fitted with 
conventional air-conduction hearing aids. 
Research has shown that the direct, percutaneous, BCD is more effective than 
an indirect, transcutaneous, BCD10,11, which is logical, given that the direct BCD 
bypasses the skin and subcutaneous layers where sounds can be lost. 
Three generations of Baha sound processors have been developed, all with 
different degrees of strength: the, so-called, Baha Compact/Divino, the Baha 
Intenso, and the Baha Cordelle. Dun et al.12 described the speech recognition 
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scores of a group of Baha users based on Baha type and related these scores to 
the users’ sensorineural hearing loss component. Based on these data, Dun and 
colleagues formulated indication levels. The Compact/Divino is suitable for 
individuals with bone conduction thresholds better than 30 dB HL. This 
suggests that the Compact/Divino device “compensates” for the conductive 
hearing loss component and in addition it can “compensate” for a sensorineural 
hearing loss of maximum 30 dB HL. The Baha Intenso is appropriate for 
individuals with up to a 45 dB HL sensorineural hearing loss component. The 
Baha Cordelle is the most powerful Baha; it comprises a transducer and a 
separate body-worn amplifier and can be used by patients with a sensorineural 
hearing loss component of up to 60 dB HL. 
 
 
 
 
 
 
 
 
 
 
 
 
1. Audio processor  
2. Titanium abutment 
3. Fixture / Implant 
 
 
 
 
 
 
 
 
Figure 6. The Bone-Anchored Hearing Aid. Source: Cochlear Benelux. 
 
Middle ear implant, extended indications 
The VSB was developed, as described above, for patients with sensorineural 
hearing loss. A recent development is the use of a VSB for patients with 
conductive or mixed hearing loss. In such cases, the FMT should be coupled 
directly to remnants of the ossicular chain or the cochlea itself. Colletti and 
General introduction 
 
 
 
 21 
colleagues were the first to report results on patients with mixed hearing loss 
who were implanted with a VSB13. They connected the FMT directly to the round 
window membrane of the cochlea (Figure 7). Another option is to connect the 
FMT to a remaining stapes structure in the oval window. 
The use of the VSB in mixed hearing loss is relatively new and has not yet been 
optimized. For instance, the FMT has not been adapted to suit this new 
technique: the same FMT is used as that optimized for conventional application 
(viz. clipped to the long process of the incus). Coupling devices have been 
designed and are clinically available to accommodate the FMT for various 
applications in the middle ear14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The Vibrant Soundbridge; the floating mass transducer is connected to the round window 
membrane. Source: Med-El. 
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Aim of the thesis 
 
In the past, the only option for hearing rehabilitation in patients with hearing 
loss was an acoustic hearing aid. Nowadays, more options are available and the 
choice depends on the type and severity of hearing loss and the pathology of 
the ear. This thesis aims to describe the different rehabilitation options for 
patients based on their hearing loss classification. Implantable hearing devices 
are classified as active implants when they have an electric power source. In 
contrast, ossicular replacement prostheses are not electronically controlled and 
are therefore classified as passive hearing implants. Chapter 2 of this thesis 
describes the hearing rehabilitation possibilities for patients with sensorineural 
hearing loss from an audiological point of view. The simplest hearing 
rehabilitation option for this patient group is the conventional air-conduction 
hearing aid. Alternative options are implantable hearing aids such as a CI or a 
MEI. Each hearing aid has its own indication criteria, in which factors such as 
the extent of the hearing loss and the condition of the external auditory canal 
and the middle ear play a significant role. When advising a patient on a specific 
implantable hearing aid, it is important to know the output characteristics of 
the implant. Manufacturers often claim broad indication ranges for their 
implants and different implant indication ranges overlap. To understand the 
outcomes of a specific implant device, for research purposes it is imperative 
that each patient has had sufficient time to use the device before assessing 
hearing outcomes. We have chosen to evaluate the aided speech recognition 
data as a measure of patient performance with an implant. Such data reflect the 
capabilities of active implants in these patients and are useful to construct an 
application diagram. In chapter 2.1 we present a study in which we determined 
such application ranges for different hearing aids in patients with sensorineural 
hearing loss. Cost-effectiveness or surgical aspects were not taken into 
consideration.  
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In several countries, hearing aid purchase costs are fully or partially covered by 
insurance companies. For insurance companies cost is a major issue. Unlike 
acoustic hearing aids, implantable hearing aids have an additional medical cost 
attached to their use. This added financial cost has led to questions being 
raised on the cost effectiveness of implantable devices. In chapter 2.2 we 
review four studies that reported quality of life as an outcome measure of 
middle-ear implantation in patients with sensorineural hearing loss related to 
costs. 
 
Chapter 3 describes the application of MEIs in patients with mixed hearing 
loss13. As this is a relatively new technique and not yet optimized for this 
application, there is still debate on the best fixation position and coupling of 
the FMT. If the stapes is present and mobile, there is debate whether the FMT 
should be connected to the stapes or placed in the round window niche14. 
Intraoperative measurements of hearing thresholds with the FMT in different 
positions might be of help to determine the best position of the FMT. Chapter 3 
describes six patients with mixed hearing loss who were implanted with a VSB. 
In four of the six patients, intraoperative objective measurements were 
performed using auditory steady state responses (ASSR). ASSR thresholds were 
measured while the FMT coupling to the cochlea was manipulated to find the 
most effective coupling. This study is presented in chapter 3.1. One of the six 
implanted patients is specifically addressed in chapter 3.2. This chapter 
describes the audiological story of a patient who was implanted with a VSB in 
the classic way because of a sensorineural hearing loss. However, a gradual 
deterioration in hearing thresholds occurred caused by necrosis of the long 
process of the incus. Another coupling was made for the FMT, interposed 
between the stapes and the tympanic membrane. It was the first patient in our 
clinic with a mixed hearing loss using a VSB. Later, five more patients with 
mixed hearing loss were selected for implantation with a VSB with the FMT 
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connected directly to the cochlea. The audiological long-term results from the 
six patients are described in chapter 3.3. 
 
Chapter 4 describes the change in hearing rehabilitation device in 5 patients 
with a profound mixed hearing loss. Initially these patients fulfilled the 
application criteria for a Baha Cordelle, the most powerful Baha. However, as 
hearing levels deteriorated over time, the Baha Cordelle became inadequate. 
These patients changed from the the Baha Cordelle to a CI.  
 
Finally, Chapter 5 presents a general discussion regarding the findings 
presented in the preceding chapters. This chapter focuses on how to deal with 
overlapping device indication criteria and conclusions are drawn on how to 
select the most appropriate hearing device for a patient.  
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Abstract 
 
Objective: To define audiological application criteria for different implantable 
hearing aid devices. 
 
Methods: Retrospectively, comparisons were made between aided speech 
recognition scores obtained at conversational level (65 dB) in patients with the 
Vibrant Soundbridge (VSB) (n=22), the Otologics middle ear transducer (MET) 
(n=10), conventional hearing aids (behind-the-ears) (n=47) and cochlear 
implants (CIs) (n=123).   
 
Results: In relation to hearing loss, only for mild hearing loss, speech 
recognition scores with VSB were comparable to that with conventional hearing 
aids. In the Otologics MET users, speech recognition scores were comparable 
with those of the conventional hearing aid users until a mean hearing loss of 
about 75 dB HL. At a sensorineural hearing loss of about 65 dB HL or more, the 
Otologics MET users have better speech recognition scores than the VSB users. 
For comparison with CI users, we followed a more conservative approach. In 
90% of the users of a CI, speech recognition scores were better than those in:  
§ patients with a conventional hearing aid and a mean hearing loss of about 
95 dB HL or worse; 
§ patients with an Otologics MET and a mean hearing loss of 85 dB HL or 
worse. 
 
Conclusions: Patients fitted with a VSB or an Otologics MET middle ear implant 
do not demonstrate better speech recognition scores than patients fitted with 
today’s conventional hearing aids. Results might even been worse. However, the 
VSB and Otologics MET are a good option in patients with moderate (VSB) to 
severe (Otologics MET) sensorineural hearing loss and external otitis. 
Audiological application criteria for otologic active implants 
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Introduction 
 
In the past, for a person with sensorineural hearing loss (SNHL), the only 
option was to fit a conventional hearing aid. Nowadays, more options are 
available and the choice depends on the type and severity of hearing loss. The 
simplest noninvasive option remains a conventional air-conduction hearing aid, 
which comes in two types: in-the-ear and behind-the-ear (BTE). One 
disadvantage is that these devices occlude the ear canal, so they are 
contraindicated in some patients, e.g. who have chronic external otitis. Another 
disadvantage is that they may provide insufficient benefit when the hearing 
loss is severe. Alternative options are invasive hearing aids that require surgery 
before they can be used. These comprise a bone-anchored hearing aid (BAHA), a 
cochlear implant (CI) or a semi-implantable middle ear device. The BAHA uses 
the principle of bone conduction to enable hearing. Sounds are transmitted 
directly to the cochlea via vibration of the skull1,2. Thus the external ear canal 
and middle ear are by-passed. It is not the most suitable device for SNHL, 
because the most powerful BAHA (BAHA Cordelle) just provides 10-15 dB 
“compensation” of the sensorineural component at its maximum capacity3. 
Consequently, the application criteria for BAHA are not addressed here. A CI 
directly stimulates the auditory nerve and is indicated in persons with profound 
hearing loss whose auditory nerve is intact4. Semi-implantable middle ear 
hearing aids directly drive the ossicular chain, via an implanted transducer 
connected to it (Figure 1), and by-pass the external ear canal and tympanic 
membrane. The patient’s ear canal remains open. The main reason for 
implantation of a middle ear implant (MEI) is not cosmetic, rather medical 
reason in subjects with chronic external otitis who cannot tolerate occlusion of 
the external ear canal. Currently, two semi-implantable MEI systems are 
commercially available: the Vibrant Soundbridge (VSB; Med-El, Innsbruck, 
Austria)5-7 and the Otologics Middle Ear Transducer (Otologics MET; Otologics 
LLC, Boulder, Colorado, USA)8. MEI manufacturers claim a broad indication range 
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in terms of dB hearing loss as well as better performance than with 
conventional hearing aids6,9,10. In addition, studies have suggested better sound 
quality with a MEI than with a conventional hearing aid9,10.  
In the present study, the application ranges in dB of two MEI systems, 
conventional BTEs and CIs were evaluated using speech perception data from 
groups of patients with SNHL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cross-sectional view of the Vibrant Soundbridge, with the Floating Mass Transducer (FMT) 
attached to the incus. Source: Vibrant MED-EL. 
 
Materials and Methods 
 
Speech recognition data on four groups of patients with SNHL, who were 
experienced hearing aid users, were obtained from the database at the 
Audiological Centre of the Radboud University Medical Centre Nijmegen, the 
Netherlands. The groups were using state-of-the-art BTE digital hearing aids 
(e.g. Widex Bravo series, Oticon Tego series or Danavox DFS devices) that had 
been (re)fitted in the period 2004-2006 (group 1; n=47), CIs (group 2; n=123) 
or a MEI: VSB (group 3; n=22) or Otologics MET (group 4; n=10). Patients 
(except the patients with a CI) were selected from this database on the basis of 
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the following criteria: pure SNHL (air-bone gap at the frequencies 0.5-4 kHz of 
<10 dB); measurable thresholds from 0.5 to 4 kHz (<120 dB HL); mean hearing 
loss at 0.5, 1 and 2 kHz of <100 dB HL; flat or mildly sloping audiogram 
(difference in thresholds at 0.5 kHz and 4 kHz of <35 dB), and younger than 70 
years of age. The MEI users all had chronic, therapy-resistant external otitis 
that had led to the choice of this type of device. The patients with the VSB 
used either the 304 or 404 audio processors and the Otologics patients all used 
the Button device. All the selected patients were experienced hearing aid users 
(> 5 years) who had been fitted at the Nijmegen Audiological Centre and 
evaluated using the same protocol. The protocol of the fitting procedure uses 
the National Acoustics Laboratories-Non-Linear rule11 for initial programming of 
the BTE and MEI devices. If the patient was unsatisfied with the first fitting 
result, the device was immediately fine-tuned. After 4 weeks of device use, the 
result was evaluated and the device was further fine-tuned, depending on the 
remarks of the patient. At a third visit, 4 weeks later, the device was checked 
and free-field measurements were performed. The CI users were all postlingually 
deaf adults of younger than 70 years, with a healthy bone structure of the 
cochlear shell. They were all using second generation multichannel systems 
(Nucleus 24 or Clarion HiFocus) that had been implanted between 1998 and 
2005. CI users with otosclerosis, an obliterated cochlea or a malformed cochlea 
were excluded. Data had been obtained in the sound field in the same way as in 
the other patients; the evaluated data were obtained at 1-year follow-up and 
were used in the present study, because in CI users, speech recognition 
improves over time and stabilizes largely after about 6 months of CI use12. The 
following audiometric data were analyzed:  
§ monaural speech audiogram (graph of speech recognition score vs. speech 
intensity) measured using headphones;  
§ monaural aided speech audiogram in the sound field. Phoneme scores had 
been obtained using standard lists of 13 phonetically balanced consonant-
vowel-consonant words13.  
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Figure 2 shows a typical example of an (un)aided speech audiogram and 
introduces the two measures used in the analyses:  
§ The maximum phoneme score (MPS; i.e. the highest score obtained using 
headphones, irrespective of presentation level). 
§ The aided phoneme score in quiet at an input level of 65 dB sound pressure 
level (PS65), thus at normal conversational level.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Speech audiogram (speech recognition score vs. speech intensity) of a patient with an 
Otologics middle ear transducer. Unaided scores were measured with headphone, aided scores were 
measured in sound field.  
MPS: maximum phoneme score measured with headphones in the unaided condition; PS65: aided 
phoneme score in quiet at an input level of 65 dB sound pressure level. 
 
All the measurements were carried out in a sound treated double-walled booth 
and were performed with unilateral hearing device use whereas the second ear 
was occluded with an earplug and earmuff. Only unilateral scores were 
considered because the MEIs and CIs are only applied unilaterally at our clinic.    
 
Individual speech scores (MPS or PS65) were plotted against individual mean 
SNHL component at 0.5, 1, 2 kHz. A nonlinear regression curve of the second 
order was fitted though the individual data using the GraphPad Prism 4 
software.  
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Results  
 
Speech recognition in patients with digital conventional hearing aids (BTE 
users) 
Figure 3 shows the PS65 scores of the BTE reference group and the fitted 
nonlinear regression curve (the full line). A second nonlinear regression curve 
was fitted through the MPS data (the dotted line; individual MPS data are not 
presented). The MPS line can be considered as the best score possible. The aims 
of fitting a hearing aid might be to achieve speech recognition scores that are 
close to the MPS. The figure shows that the PS65 line is close to the MPS line, 
which suggests good speech recognition with the BTE. This validates the 
hearing aid fitting procedures and demonstrates that limitations in today’s BTE 
benefit are more likely to have a physiologic cause than a technologic cause.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. (Monaural) individual aided phoneme scores in quiet at 65 dB sound pressure level (PS65) 
from conventional hearing aid (behind-the-ear (BTE)) users as function of their mean sensorineural 
hearing loss (SNHL). The two lines are best fitted nonlinear regression lines. 
P10-CI: 10th percentile of PS65 scores in a group of patients with a cochlear implant (CI); p50-CI: 
median of PS65 scores in a group of patients with a CI; MPS: Maximum Phoneme Score. 
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Speech recognition in patients with semi-implantable middle ear prosthesis 
Figure 4 shows the PS65 data of the VSB group and the fitted nonlinear 
regression curve. For reference purposes, the PS65 line for BTE fittings, taken 
from Figure 3, is added. The scores of most of the VSB users were below the 
PS65 BTE line, which suggests that in the pure-tone average range analyzed in 
this study, the VSB was unable to achieve the same performance level as the 
BTE. Figure 5 shows the PS65 data in the Otologics MET users. The PS65 BTE line 
and the PS65 VSB line are also shown. It can be seen that the PS65 scores of 
the Otologics MET are higher than the PS65 line of the VSB group and that they 
cluster around the PS65 BTE line until a mean SNHL of about 75 dB HL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. PS65 values with the Vibrant Soundbridge and the best fitted nonlinear regression line 
(full line). The best fitted PS65 line of the BTE group is shown as a reference. 
 
Speech recognition in patients with cochlear implants 
For the whole group of CI users, the median (p50) PS65 value is 74%. In 
addition, we calculated the p10 value as indicated in Figure 3; the p10 PS65 
value was 42%, thus 90% of the CI users had a PS65 score of higher than 42%.  
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Conventional hearing aids and middle ear implants compared to cochlear 
implants 
The median PS65 score in the CI users was 74%. In the BTE users, a comparable 
score was seen at a mean SNHL of about 80 dB HL (Figure 3). In other words, in 
patients with a mean SNHL of 80 dB or more on the average, a CI would lead to 
better speech recognition scores than a BTE. However, out of all the possible 
hearing rehabilitation systems, a CI is the most invasive and most expensive 
option and it involves the highest peroperative risk. Therefore, to define 
application criteria for the CI on an individual level, we use the more 
conservative p10, instead of the p50. The p10 value in the CI users was 42%. In 
the BTE users, this PS65 value was reached at a mean SNHL of about 95 dB HL 
(Figure 3). In other words, if the mean hearing loss is 95 dB HL or more, 90% of 
the patients would achieve better speech recognition scores with a CI than with 
a BTE. A similar evaluation using the p10 value was applied to compare CI and 
MEI data, more specifically to the most powerful MEI (Otologics MET; see Figure 
5). It suggested that in the patients (who could not tolerate an ear mold) 
whose mean SNHL exceeded 85 dB HL, 90% would have achieved better speech 
recognition scores with a CI than with this powerful MEI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. PS65 values with Otologics middle ear transducer (MET) and the best fitted nonlinear 
regression line. The best fitted PS65 lines of the BTE group and Vibrant Soundbridge group are 
shown as references. 
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Application criteria for hearing aids in different patient groups  
Based on the calculated PS65 scores, we can determine audiological application 
criteria for individual devices. 
 
1. Patients with sensorineural hearing loss without external otitis  
(SNHL - EO) 
The evaluation values indicated that BTEs are the first choice up to a SNHL 
of 95 dB HL. Above that level, 90% of the CI recipients achieved better 
speech recognition scores than the BTE users. When SNHL - EO patients 
should have MEIs, our data suggested better speech recognition with the 
Otologics MET than with the VSB. The upper limit of application for the VSB 
was set at a mean SNHL of 65 dB HL. At this threshold, the PS65 line of the 
VSB was 10% lower (arbitrary choice) than the PS65 line of the Otologics 
MET and the discrepancy continued to increase with increasing SNHL. In a 
similar way, the upper limit of application for the Otologics MET was set at 
80 dB HL. At this threshold, the PS65 with a BTE was likely to be at least 
10% higher than with the Otologics MET. 
2. Patients with sensorineural hearing loss and external otitis  
(SNHL + EO)  
A BTE is not an option in this group of patients. Consequently, we defined 
as upper application for the Otologics MET a (mean) SNHL of 85 dB HL, i.e. 
the mean hearing loss at which the PS65 with the Otologics MET was 42% 
(Figure 5) and thus equal to the p10 value in the CI users. In other words, 
if the mean SNHL of a newly referred patient is 85 dB HL or poorer, the 
PS65 score with the Otologics MET will probably be 42% or less, whereas 
with a CI a patient is likely to achieve a phoneme score of 42% or more.  
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Discussion 
 
Results were available on 47 BTE users, 123 CI users, 22 VSB users and 10 users 
of the Otologics MET. The hearing capacity of patients fitted with today’s digital 
conventional hearing aids (BTEs) is close to target values as presented with the 
MPS values. Furthermore, scores with the VSB and Otologics MET were not better 
than those with a state-of-the-art BTE. Based on these conclusions, we formed 
audiological application criteria for implantable hearing devices for patients 
with SNHL. 
 
With the aid of information on the gain-frequency characteristics of MEIs, these 
straightforward application limits can be shaped into frequencies. Previously, 
maximum gain-frequency relations were determined in a group of patients with 
the VSB and in another group with the Otologics MET14. By using these 
frequency-gain data as input, the National Acoustics Laboratories-Non-Linear 
rule11 can be used backwards to obtain frequency-specific hearing thresholds 
instead of mean hearing thresholds. The NAL rule is a well validated 
prescription method that prescribe desired target gain based on hearing 
thresholds. Figures 6 and 7 show the results. The  lower limits of application for 
the VSB and Otologics MET were given by the manufacturers. Every hearing 
device has such lower application limits, owing to the noise level of the device. 
The data in Figures 6 and 7 are not intended for rigid application, but can be 
used as a practical guideline. 
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Figure 6. Audiological application criteria for implantable hearing devices in patients with 
sensorineural hearing loss (SNHL) without external otitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Audiological application criteria for implantable hearing devices in patients with 
sensorineural hearing loss (SNHL) and external otitis. 
 
It should be noted that the MEIs described in this report comprised 
commercially available semi-implantable devices. The Otologics fully 
implantable device (Otologics Carina) is less powerful in terms of functional 
gain15, so the indicated Otologics MET application range does not apply for that 
device. 
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Furthermore, it’s important to note that the described application criteria are 
based on an audiological evaluation; cost-effectiveness or surgical aspects were 
not taken in consideration. Moreover, the application diagrams are only 
applicable to patients with flat or mildly sloping audiograms.  
 
Evaluation method 
The present analyses were based on speech recognition scores in quiet 
surroundings obtained from experienced hearing aid users, listening monaurally. 
This can be considered as a conservative approach that revealed the most basic 
and effective treatment outcomes. Cost-effectiveness considerations in current 
patient management practice are important reasons for unilateral hearing aid 
application of implants. In comparing different hearing devices, speech 
recognition scores in quiet surroundings were preferred to speech recognition 
scores in noise. In patients with unilateral amplification and bilateral hearing 
loss, speech perception in noise will be impaired anyway as they have no access 
to spatial cues. Furthermore, digital devices might have processing algorithms 
to improve speech recognition in noise, which impedes a comparison between 
different hearing devices.  
The patients in this report were selected on the basis of a flat or mildly sloping 
audiogram, therefore amplification was achievable in the whole frequency range 
from 250 to 8000 Hz. In patients with ski-slope audiograms, it is often hard to 
find a good balance between amplification in the low and high frequencies. So, 
in comparing the different kinds of hearing devices, we choose to use patients 
with a relatively flat audiogram to make the group more homogenous. For the 
same reason, we excluded patients older than 70 years.  
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In conclusion, when hearing loss is not too severe, a semi-implantable middle-
ear device is a good option in patients with a SNHL and external otitis. In 
patients without external otitis, a semi-implantable middle ear device and a BTE 
are at least competitors in audiological terms. However, announced technical 
updates might lead to wider inclusion criteria for MEI application in the near 
future.  
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Abstract 
 
Objective: To assess the relation between cost and effectiveness of implantable 
middle ear hearing devices in patients with pure sensorineural hearing loss.  
 
Design: Literature review. 
 
Results: Four studies were identified that described the effect of middle ear 
implantation on quality of life in groups of at least 20 patients. Several 
different quality of life questionnaires were used.  
 
Conclusions: Our review demonstrated that middle ear implantation is a cost-
effective health care intervention in patients with sensorineural hearing loss 
who suffered from an additional therapy-resistant chronic external otitis.   
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Introduction 
 
Middle ear implantation is a relatively new treatment for patients with 
sensorineural hearing loss who do not benefit from conventional hearing aid 
fitting. Todays middle ear hearing aids are still semi-implantable devices. They 
comprise an audio processor, with microphone, electronics and FM transmitter, 
which is worn externally. The audio processor is in (magnetic) contact with an 
implanted receiver unit, placed just below the skin in the mastoid region1. This 
receiver is connected to the output transducer that is coupled to one of the 
middle ear ossicles. 
Recently, middle ear implants have been applied to patients with conductive or 
mixed hearing loss. The transducer is coupled directly to the cochlea via one of 
the cochlear windows2. 
In contrast to a conventional hearing aid, the application of a middle ear 
implant involves surgery and much higher financial cost. These features have 
led to health-economic questions regarding treatment effectiveness in relation 
to the cost.  
Let us first consider effectiveness. To assess the effect of a medical intervention 
on a patient’s feeling of well-being, questionnaires are often administered. One 
option is the use of generic health-related quality of life (HR-QoL) 
questionnaires, such as the Short Form 36 (SF-36)3,4, the EuroQol5 or the Health 
Utility Index6. In principle, these HR-QoL questionnaires are not disease-
specific and can therefore be applied across the borders of a specific disability. 
The main outcome of most generic HR-QoL questionnaires is one single measure 
called utility. It ranges between 1 (perfectly happy) and 0 (death). The change 
in utility owing to a specific intervention is called the utility gain and it is used 
to determine the quality-adjusted life-years or QALYs. A QALY is the utility gain 
in a group of patients multiplied by the life expectancy after the intervention7,8. 
The second option is to use hearing handicap-specific QoL questionnaires.  
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Several studies that used generic HR-QoL questionnaire scores showed only 
small changes in utility gain after conventional hearing aid fitting9. This is in 
direct contrast with handicap-specific questionnaires that mostly demonstrated 
significant improvements10. It has been concluded that most generic HR-QoL 
questionnaires are not sensitive to problems associated with audition and 
communication9,11. Furthermore, when different HR-QoL questionnaires were 
used in parallel to assess the benefit of hearing interventions, wide inter-
questionnaire variability was found11,12. Therefore, handicap-specific 
questionnaires have been introduced to measure QoL after hearing interventions 
and they have become very popular. Examples are the Glasgow Benefit 
Inventory13, the Nijmegen Cochlear Implant Questionnaire14,15 and the 
International Outcome Inventory for hearing aid provision16. These 
questionnaires have well-described structures and have been validated; 
however, they do not provide utility scores. Let us take a closer look at these 
questionnaires. 
 
The Glasgow Benefit Inventory (GBI)   
The GBI is a HR-QoL questionnaire that was specially developed to measure 
outcomes of otorhinolaryngological interventions; it is a retrospective 
standardized questionnaire that examines the impact of the treatment on the 
health status of the patient13. Scores can range from –100 (profound 
deterioration) to +100 (excellent improvement). Twelve out of the 18 questions 
are about general health, 3 questions concern social functioning and 3 concern 
physical health. The GBI has been used successfully to evaluate the bone-
anchored hearing aid17 and cochlear implants18.    
 
The Nijmegen Cochlear Implant Questionnaire (NCIQ)  
The NCIQ is an HR-QoL questionnaire that was specially developed to assess 
longitudinal health status after cochlear implantation14,15. It addresses three 
functional domains: physical (communication related), social and psychological 
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functioning. Each subdomain contains at least 10 items. The overall scores per 
subdomain range from 0 (very poor) to 100 (optimal). 
The three domains showed acceptable consistency statistics, test-retest 
coefficients and responsiveness indexes14,15. In a long-term follow-up study on 
adults with cochlear implants, the NCIQ scores were fairly consistent over 
time19. Nowadays, the NCIQ is being widely used19-23. It has been used for 
example to compare quality of life between cochlear implant users and hearing 
aid users with severe hearing loss19,23. 
 
The International Outcome Inventory for Hearing Aids (IOI-HA) 
This seven-item, self-report survey has been translated into more than 20 
languages16. Each of the seven items targets a different field, namely daily use, 
benefit, residual activity limitation, satisfaction, residual participation 
restriction, impact on others and quality of life. Scores range from 1 (poor) to 5 
(optimal). The psychometric properties have been studied extensively and norms 
have been established from large groups of conventional hearing aid users16. 
 
Cost-utility ratio of hearing intervention   
The direct cost of treatment can be divided into the phases of selection, 
implantation and rehabilitation7,8,24. To calculate the cost-per-QALY of middle 
ear implantation, we need to know the direct cost and utility gain. However, 
owing to the variation in utility scores across generic HR-QoL questionnaires, as 
referred to above, such calculations are not straightforward. Let us look at the 
cost-per-QALY determination of conventional hearing aid fitting according to 
Grutters et al.12. They used four different generic HR-QoL questionnaires in 
parallel to assess a group of 315 patients who had been fitted with hearing aids 
for the first time. Utility gain values obtained with the four questionnaires 
differed by a factor of 40 and, as a consequence, the calculated cost-per-QALY 
also differed by this unacceptable range of 40. Thus the cost-per-QALY seems to 
primarily depend on the generic HR-QoL questionnaire used and not on the 
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effectiveness of the intervention or its cost. Therefore, any health-economic 
evaluation of hearing interventions based on the cost-per-QALY concept can be 
questioned. 
Handicap-specific QoL might form an alternative way to assess cost utility. As 
cochlear implantation in postlingually deaf adults has an acceptable cost-utility 
ratio7,8,25, the effectiveness of a new type of implantation might be determined 
by comparing the outcomes of handicap-specific QoL questionnaires after the 
new treatment to those of cochlear implantation. Next, the cost of the new 
intervention must be calculated and compared to that of cochlear implantation. 
Based on the relative effectiveness and the relative cost, it can be concluded 
whether or not the new treatment is more or less cost-effective than cochlear 
implantation17.  
 
Quality of life and middle ear implantation: a review of the literature 
QoL in relation to middle ear implantation was studied in a substantially large 
group of patients (n>20) in four papers26-29. Sterkers et al.27 published the 
results of a French multicentre trial on patients with pure sensorineural hearing 
loss, implanted with the Vibrant Soundbridge middle ear hearing device (Med-
El, Innsbruck, Austria). They used the inclusion criteria advocated by the 
manufacturer. Recently, long-term data have been published on the same 
group28. To evaluate patient benefit, the GBI was used. In 57 patients, the 
mean overall improvement was 15 points (on the scale from -100 to +100) in 
the initial study and 18 points in the long-term study27,28. Table 1 presents the 
mean scores on each of the three GBI subscales. 
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Table 1. Mean GBI data from 3 different studies: total score and mean scores per subdomain are 
presented. 
 
Schmuziger et al.29 published their retrospective data on a group of 20 Vibrant 
Soundbridge users with pure sensorineural hearing loss. They also employed the 
inclusion criteria advocated by Med-El. The GBI and the IOI-HA were applied to 
obtain data. Overall improvement on the GBI was 15 points (Table 1), while the 
IOI-HA showed an overall postintervention score of 3.7 (on a scale from 1 to 5). 
For reference purposes, the authors compared their results to the norm data 
reported by Cox et al.16. After conventional hearing aid fitting, the mean norm 
score in the latter study was 3.6, which was almost the same as the IOI-HA 
score from the middle ear implant users.   
Snik et al.26 presented the results of a prospective quality of life study on 21 
patients with sensorineural hearing loss who received a middle ear implant. The 
devices comprised either the Vibrant Soundbridge or the Otologics MET 
(Otologics Company, Boulder, Colorado, USA). Treatment cost was determined 
based on the direct cost of implantation, rehabilitation and one year of 
aftercare. The total cost was EUR 14,354 per middle ear implant, irrespective of 
the type. To assess effectiveness, the patients filled out the generic SF-36 and 
NCIQ before implantation and at 6 and 12 months after implantation26. The GBI 
was filled out once, between 6 and 12 months after implantation. In contrast 
with the other three papers, the patients described, by Snik et al. were all 
Study Snik26 Sterkers27 Mosnier28 Schmuziger29 
Number of patients 17 57 62 20 
GBI score: 
Total 32.9 15.4 17.8 14.7 
General score 41.5 20.0 22.8 22.1 
Physical health 15.7 0.0 1.7 -5.0 
Social interaction 17.6 11.5 14.1 5.0 
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suffering from chronic, therapy-resistant external otitis. The SF-36 outcome 
showed only minimal improvement after the intervention. In agreement with 
Brazier et al.4, the mean utility gain on the SF-36 was 0.01 (on a scale from 0 
to 1). This small improvement in SF-36 utility is explained by the statement in 
the Introduction section that most generic HR-QoL questionnaires are too 
insensitive to hearing problems. Based on this utility gain, the cost-per-QALY 
was high: it exceeded EUR 70,000. In contrast, all three domains of the NCIQ 
showed substantial improvement in the scores after middle ear implantation 
(p<0.01), while the mean GBI score was 33 points, which indicated highly 
significant improvement (p<0.001).  
Next, Snik et al.26 compared the middle ear implantation NCIQ subscale scores 
to those obtained in their previously cochlear implant study on postlingually 
deaf adults14,15. Analyses showed that cochlear implantation was 1.5 to 2.5 
times more effective than middle ear implantation, whereas, middle ear 
implantation was 3.3 times cheaper than cochlear implantation. These findings 
suggest that middle ear implantation is more cost-effective than cochlear 
implantation. 
The GBI score in the study by Snik et al.26 was considerably higher than that 
reported in the other studies (Table 1). This might have been due to their 
inclusion criterion of external otitis. Such patients cannot tolerate an ear mold, 
or they can only tolerate the occlusion for a few hours per day. A middle ear 
implant enabled these patients to hear again without any pain or itching in the 
ears. Table 1 shows that this group of patients had higher GBI scores 
throughout. The most profound difference was seen in the physical health 
domain.  
As stated above, all the patients studied by Snik et al.26 had comorbid external 
otitis in contrast with the Sterkers et al.27 and Schmuziger et al.29 whose 
patients comprised dissatisfied conventional hearing aid users alone. The 
relatively low GBI scores reported by Sterkers et al.27, Mosnier et al.28 and 
Schmuziger et al.29 indicate limited benefit. This conclusion is in agreement 
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with the post-intervention IOI-HA scores presented by Schmuziger et al. Their 
IOI-HA scores showed that middle ear implants did not have a surplus value 
compared to conventional hearing aids29. 
In conclusion, middle ear implantation seemed to be cost-effective in patients 
with sensorineural hearing loss and with comorbid chronic external otitis. Our 
literature review suggested that this conclusion may not apply to patients with 
pure sensorineural hearing loss who dislike conventional air-conduction devices 
for whatever reason and are searching for an alternative. 
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Abstract 
 
Objective: To optimize intraoperatively the coupling of the Floating Mass 
Transducer (FMT) of the Vibrant Soundbridge (VSB) middle ear implant to the 
round or oval cochlear window in patients with mixed hearing loss. 
 
Study design: Intraoperative measurement of objective hearing thresholds 
using Auditory Steady State Responses (ASSRs). 
 
Patients: Four individuals with mixed hearing loss and at least no incus, in 
need for a middle ear implant. 
 
Intervention: Surgical placement of the Vibrant Soundbridge. ASSR thresholds 
were measured intraoperatively, whereas FMT coupling to the cochlea was 
manipulated to find the most effective coupling of the FMT. 
 
Main Outcome Measure: Differences in ASSR thresholds between different FMT 
coupling options within patients.  
 
Results: With ASSR, we assessed placement of the FMT in the round window 
niche, loosely or tightly packed in the niche; creation of a mobile window in 
case of a fixed stapes footplate; and FMT position coupled to the stapes that 
afforded vibration in the natural vibration direction or perpendicular to it. 
Furthermore, test-retest variations in ASSR thresholds were studied. It was 
shown that differences in ASSR thresholds could be detected, while 
manipulating the FMT couplings, which were statistically significant.  
 
Conclusions: Intraoperative ASSR measurement is a good method to study 
different positions of the FMT and to determine the best position of the FMT for 
a patient. 
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Introduction 
 
In 2006, Colletti et al.1 used the Vibrant Soundbridge (VSB) middle ear implant 
in a new surgical configuration suitable for patients with mixed hearing loss. 
They applied direct stimulation to the cochlea in 7 patients, by placing the 
floating mass transducer (FMT) in the (enlarged) round window niche. The 
results were remarkable. Since this paper by Colletti et al.1, additional articles 
have been published on the application of the VSB middle ear implants in 
patients with conductive or mixed hearing loss2-7.    
There is still debate on the best fixation position and coupling of the FMT in 
patients with mixed hearing loss. If the stapes is present and mobile, it is not 
clear whether the FMT should be connected to the stapes, or placed in the 
round window niche8. It might be of help to the surgeon to take objective 
intraoperative measurements of hearing thresholds to determine the best 
position. For this purpose, auditory evoked potentials may be useful while 
stimulating the cochlea via the implant. Short-latency electroencephalogram 
(EEG) recordings are the only option (auditory brainstem response and 
electrocochleography), because middle latency and long latency potentials are 
significantly affected by anesthetics9. However, a problem with 
electrocochleography and especially with auditory brainstem response 
measurements is the transient nature of the stimuli, which can easily be 
distorted by the speech processor (part of the implant) or the output 
transducer. Furthermore, the click-evoked potentials are non-frequency specific.  
A fairly new alternative option is to use the auditory steady state response 
(ASSR) with 90-Hz modulated continuous tones. The 90-Hz ASSR is not affected 
by anesthetics9, and the continuous stimuli are readily processed by the 
implant. The aim of this study was to test the feasibility of intraoperative ASSR 
measurements to guide the surgical placement of the FMT in patients with 
mixed hearing loss. Here, preliminary results were presented. 
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Material and Methods 
 
ASSR measurements were obtained from 4 patients with severe mixed hearing 
loss during FMT implantation. Some characteristics are presented in Table 1. 
Three of the patients (Patients 1, 3 and 4) had been experiencing chronic otitis 
media and otorrhea for many years despite multiple surgical ear procedures. 
Previously, Patients 3 and 4 had been using a bone-anchored hearing aid 
Cordelle and Patient 1 a conventional hearing aid in the infection-free 
contralateral ear. Patient 2 had symmetrical bilateral sensorineural hearing loss 
and therapy-resistant external otitis. Initially, she had been provided with a 
VSB with the FMT connected to the incus of an intact ossicular chain. After 4 
years, device failure occurred and a large air-bone gap was found in the 
implanted ear. Exploratory tympanotomy showed displacement of the FMT owing 
to necrosis of the long process of the incus.  
 
 
 
 
 
 
 
 
 
 
 
 
Patient Status  
middle ear 
Age  
(years) 
PTA bone 
conduction  
(dB HL) 
PTA total 
(dB HL) 
Final  
position FMT 
1 Subtotal 
petrosectomy 
69 53 98 Stapes 
2 Chain 
disruption 
57 65 84 Stapes 
3 Subtotal 
petrosectomy 
74 55 101 RW niche 
4 Subtotal 
petrosectomy 
55 63 116 Stapes 
 
FMT indicates floating mass transducer; PTA, mean hearing loss at 0.5, 1, 2 and 4 kHz;  
RW, round window  
 
 
 
 
Table 1. Overview of the patients’ characteristics. 
 
The equipment used to obtain the ASSRs has been described in detail 
previously10. Stimuli comprised test tones of 500 Hz and, 1, 2 and 4 kHz, 
presented with 100% amplitude modulation and 20% frequency modulation, in 
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accordance with John and Picton11. Modulation frequencies of the 4 test tones 
were 92.1, 94.2, 96.3 and 98.3 Hz, respectively. All 4 modulated test tones were 
produced by a standard audiometer (Interacoustics AD 229e; Assens, Denmark) 
and presented simultaneously via the VSB implant. The output transducer of the 
audiometer was an insert earphone (Ear tone 3A). A plastic tube (length, 60 
cm) was glued to the opening of the microphone of the VSB audioprocessor to 
convey the acoustic output.  
Responses to the stimuli were recorded with a 3-channel EEG set-up. High-
quality EEG amplifiers were used (Jager Tonnies, Helmstadt, Germany). To 
obtain the 3 channel recordings, electrodes were placed on the contralateral 
mastoid (inverting), the inion (inverting), and the vertex (Cz; non-inverting). A 
fourth electrode, which is normally placed on the ipsilateral mastoid, was 
placed on the cheek, just in front of the tragus, outside the surgical area. The 
ground electrode was placed on the contralateral cheek. This set-up enabled 3 
channel recordings. EEG signals were analogue filtered from 20 Hz (6 
dB/octave) to 3000 Hz (12 dB/octave). A gain of 100,000 was used. 
ASSRs were derived from 4.4 minutes of EEG signal recording (with software 
that was functionally similar to the MASTER software)11. Signals were sampled at 
8 kHz per channel (256 epochs of 1.024 seconds each) and averaged over 
intervals of 16 epochs and fast Fourier transformed. Frequency resolution was 
0.061 Hz.  F values of each modulated test tone were calculated by analyzing 
the signal power of the response to the corresponding modulation frequency 
against the power averaged over 60 frequency bins on either side of the 
modulation frequency that contained noise. A significance level (p value) of 
2.5% was chosen (F=3.75, signal-to-noise ratio=5.74 dB) in a 1-sided F test, to 
identify responses that were significantly above noise level. Responses were 
considered significant if the F value was significant on at least one of the 3 
recording channels.  
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To provide stimulation via the implant, we used a standard VSB audio processor 
(type 404; Med-El, Innsbruck, Austria) that was programmed in linear 
amplification mode. The output limiter was deactivated. Special options (noise 
reduction and speech enhancement features) were turned off. Device gain was 
arbitrarily set at 20 (on a scale from 0 to 80). Linearity of the audio processor 
was studied with an implant-in-the-box device (Audio Processor Adaptor; Med-
El) whereas the audio processor was driven by the audiometer that formed part 
of the ASSR equipment.  
Electrical output of the implant-in-the-box was studied at separate frequencies 
of 0.5, 1, 2 and 4 kHz. Input (acoustical) to the audio processor was raised in 
5-dB steps until the output started to level off. The audiometer reading at 
which the output leveled off, was the highest stimulation level (upper 
stimulation level) used during the measurements. 
Typically, this occurred at an audiometer setting of 55 to 60 dB.   
As the measurements were relative (i.e. ASSR thresholds with a certain FMT 
coupling compared to those with another coupling), calibration of the setup 
was of minor importance. Nevertheless, we calibrated the present equipment in 
which the output of the insert earphone was connected to the microphone 
entrance with a tube, was calibrated. The output of the insert earphone, 
connected to the audiometer, was calibrated on a 2 cc coupler, according to ISO 
389. Next, the earphone’s output was connected to the 2 cc coupler and in 
parallel to the audio processor to calibrate the present configuration. Then, the 
audio processor was coupled to the implant-in-the-box, which enabled 
measurement of the audio processor’s output as a function of the audiometer 
setting. After checking the linearity of the audio processor, several values were 
obtained with the 2 cc coupler in place and once without, to correct the 
audiometer readings. As a consequence, the ASSR thresholds are expressed in 
dB HL.   
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To check the accuracy of this calibration method, comparisons were made 
between the conventional bone-conduction thresholds and the ASSR thresholds 
obtained using the adapted audio processor in 5 patients with the classic FMT 
application and pure sensorineural hearing loss. According to the Nijmegen 
ASSR test protocol, the differences between the behavioral bone-conduction 
thresholds and the ASSR thresholds were well within the reference range as 
reported by vd Reijden et al10.  
 
Procedure at the operating theatre 
At the operating theatre, special attention was paid to achieving optimum 
grounding of the ASSR equipment. It was checked beforehand that there was no 
interference from other electrical equipment.   
ASSR thresholds were measured at 4 frequencies simultaneously, starting at 10 
dB below the upper stimulation limits of each of the 4 test frequencies. 
Whenever a significant ASSR was obtained, the stimulation level was lowered by 
5 dB. If no response was found on any of the 3 EEG channels, the stimulation 
level was increased by 5 dB. Each stimulation frequency was tested separately. 
This procedure was repeated with the FMT in different positions. To study the 
effect of coupling the FMT to the round window or oval window via the stapes, 
the ASSR thresholds were compared. In our 4 patients, the following questions 
were addressed (defined by the individual anatomic situations): 
1. What is the effect of packing the FMT in the round window niche (loosely 
vs. tightly, using Tutopatch® (Tutogen Medical GmbH, Neunkirchen, 
Germany)? 
2. If the stapes is fixed, what is the effect of creating a second mobile 
window? 
3. If the stapes is mobile, does it matter whether the FMT vibrations run in 
the natural stapes direction or perpendicular to it? 
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4. Is it better to place the FMT in the round window niche or connect it to the 
mobile stapes? 
5. In addition, reproducibility was assessed.   
 
Surgery and the postoperative healing period were uneventful. All 4 patients 
were fitted with the audio processor and 3 of them are now successful users of 
the VSB. Only Patient 2 experienced insufficient gain with the VSB (in 
comparison with the conventional device that she occasionally uses in her 
nonimplanted ear). 
 
Results  
 
At 2 and 4 kHz, ASSR thresholds were obtained from all 4 patients within the 
linear dynamic range of the setup and in all the measurement conditions. At 1 
or 0.5 kHz, no responses were obtained from Patients 2 and 3 within this range 
in some of the conditions (see below). 
 
Test-retest measurements 
Owing to time constraints, test-retest measurements were not performed 
systematically. However, at the end of the surgery, ASSR thresholds were 
measured again when the FMT was in its final position. Final measurements 
were compared to the initial measurements obtained in the same position 
(Table 2). Reproducibility seems to have been acceptable. The mean difference 
between the initial measurement and the final measurement averaged over the 
frequencies was 2.5 ± 6.5 dB. Thus, a difference of 13 dB between 2 thresholds 
was considered to be statistically significant (based on the 95% confidence 
interval). Therefore, in our further analysis, a difference that exceeded +/- 15 
dB was considered to be of importance. 
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Condition Patient Change in thresholds (dB) at 
0.5 kHz 1 kHz 2 kHz 4 kHz 
Reproducibility 
Retest minus test 1 +10 0 0 +5 
2 +5 NA +5 0 
3 +10 NA +5 +5 
4 -5 +10 0 -15 
1. Effect of packing in round window niche 
Loosely minus tight 3 NA NA -5 0 
2. Effect of stapedotomy (fixed stapes) 
After minus before 3 NA NA +10 +5 
Reprise 3 NA NA -5 0 
3. Effect of vibration direction with respect to natural stapes vibration 
Parallel minus 
perpendicular 
1 -25 -15 -5 -5 
4. Round window (RW) placement or connection to the stapes (OW) 
OW minus RW 1 -20 -5 0 -5 
 
 
NA indicates that the stimulation level was outside the dynamic range of the equipment 
 
 
 
 
Table 2. Results of repeated ASSR threshold measurements. 
 
Final individual placement location of the FMT 
In Patients 1, 2 and 4, the FMT was connected directly to the mobile stapes. 
Contrastingly, in Patient 3, it was decided to place the FMT in the enlarged 
round window niche, because the anterior crus of the stapes was fixed to the 
footplate and was immobile, whereas the posterior crus was no longer in 
contact with the stapes.  
In Patient 3 (the only final round window placement), tight or loose packing of 
the space around the FMT in the round window niche using Tutopatch® had very 
little effect on the ASSR thresholds (Table 2). As the stapes was fixed, it was 
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argued that creating a second mobile window would again enable longitudinal 
waves to pass effectively through the intracochlear fluid. However, the creation 
of a second window, by stapedotomy, only led to minor changes in the ASSR 
thresholds (also during the retest measurement).  
In Patient 1, the FMT position was tested in 2 different vibration directions: 
parallel with the natural direction of the stapes and perpendicular to it. To 
achieve vibration parallel with the natural direction of the stapes, the arm of 
the FMT clip was bent 90 degrees. Perpendicular vibration was obtained by 
simply crimping the titanium attachment clip over the stapes head. Table 2 
shows that parallel vibration seemed to be the better option.  
In Patient 1, FMT placement was also tested in 2 different positions: in the 
round window niche and in the oval window via connection to the stapes. Table 
2 shows that there was significant improvement in the ASSR threshold at 500 
Hz in the latter position with the FMT connected to the stapes. Figure 1 shows 
examples of the preoperative audiograms and the final peroperative ASSR 
threshold of Patient 1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Preoperative audiograms and final preoperative ASSR threshold of Patient 1. 
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Discussion   
 
Application of an active middle ear implant to patients with (mixed) hearing 
loss and an interrupted ossicular chain is relatively new and the procedure has 
not yet been optimized. Candidates may comprise patients with a history of 
chronic otitis media, congenital ear canal atresia, or disconnection of the 
ossicular chain due to other causes. The FMT of the VSB has not been adapted 
for this new application. Therefore, we had to use the standard VSB, optimized 
for conventional application, that is, clipped to the long process of the incus, 
hanging freely and moving in parallel with the stapes11-13. Thus, at present, 
clinical applications precede technological developments. Little is known about 
the best position of the FMT in patients with conductive hearing loss, or about 
how to achieve the most effective transmission of the FMT vibrations to the 
cochlea in individual patients. In this study, we used frequency-specific ASSRs 
to measure intraoperative hearing thresholds in an attempt to find effective 
solutions. Preliminary results were shown. A limitation of the ASSR set-up was 
the upper stimulation level of the audiometer (approximately 55-60 dB), owing 
to the restricted dynamic range of the audio processor that is (still inevitably) 
required to provide stimulation. When we applied the data from the calibration 
procedure, these levels were comparable with approximately 70 to 80 dB HL. To 
determine reliable ASSR thresholds in patients with more severe sensorineural 
hearing loss components, it is necessary to avoid the audio processor by, for 
example, direct stimulation of the FMT. However, this type of stimulation is not 
available.       
Another limitation was the extra time needed during surgery:  in the order of 15 
to 20 minutes per threshold measurement (for 4 frequencies simultaneously).  
Based on the 95% confidence interval of the test-retest measurements, it 
seemed that a change of 15 dB or greater in ASSR thresholds was relevant. 
Obviously, 15 dB is also a limitation, but from a clinical point of view, effects in 
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the order of 5 to 10 dB might be of minor importance for final (postsurgery) 
VSB fitting because they can be compensated for by adjusting the gain of the 
audio processor.  
In summary, intrasubject ASSR measurements during surgery were informative 
and helpful to guide FMT placement in individual patients. Until it becomes 
clear which is the best position of the FMT in patients with conductive or mixed 
hearing loss, it is recommended that surgeons take intraoperative 
measurements to determine the best FMT position. ASSR is a suitable method, 
but it does take extra time during surgery.  
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Abstract 
 
Hypothesis: The floating mass transducer (FMT) of the Vibrant Soundbridge 
(VSB) can be interposed in the middle ear in case of an absent incus. 
 
Background: The VSB is a middle ear implant in which the FMT is attached to 
the long process of the incus to directly drive the ossicular chain. In this case 
report, there was gradual deterioration in speech perception after VSB fitting 
and deterioration in hearing thresholds. During exploratory resurgery, it became 
clear that the ossicular chain was interrupted due to necrosis of the long 
process of the incus. The VSB could no longer function, because there was no 
connection between the incus and stapes. 
 
Methods: Reconnection of the FMT to the anterior crus of the stapes on 1 side 
and the tympanic membrane on the other side. 
 
Results: Reconnection of the FMT to the stapes head led to obvious 
improvement in audiometric results. The air-bone gap was reduced from 
approximately 35 dB to approximately 25 dB, which indicated that the 
construction with the FMT was working like a partial ossicular replacement 
prosthesis. At 1.5 years follow-up, the aided hearing thresholds of 
approximately 45 dB HL were slightly poorer than those measured after the first 
procedure with classical positioning of the FMT. However, the speech 
recognition score in quiet at 65 dB sound pressure level was 70% with the 
classical FMT application and with the FMT connected between the stapes and 
tympanic membrane. 
 
Conclusion: It could be concluded that when the incus is absent, placement of 
the FMT directly on to the stapes is an acceptable solution.   
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Objective 
  
To present a patient with a floating mass transducer (FMT), which was used for 
the first time in a middle ear with an absent incus. To evaluate the results, 
aided threshold measurements and speech recognition tests were performed. In 
addition, maximum gain and output of this new application were compared with 
the previous classical application of the FMT to the incus.  
 
Patient and Interventions 
  
In 1999, a 63-year-old lady with symmetrical sensorineural hearing loss was 
referred to our clinic. Her hearing loss had shown slight progression in both 
ears over time. The cause was unknown. She also had therapy-resistant external 
otitis as a result of using an ear mold as part of a conventional air-conduction 
hearing aid. The audiogram at presentation revealed a mean sensorineural 
hearing loss of approximately 55 dB hearing level (HL; Figure 1A) in both ears.  
We decided to implant a Vibrant Soundbridge in the right ear and noted that 
she had a very gracile long process of the incus. In an attempt to achieve 
optimal fixation of the FMT to this gracile long process of the incus, the grip of 
the FMT was crimped carefully and repeatedly. Nevertheless, fixation was not 
considered to be optimal, so bone cement (SerenoCem®; Corinthian Medical Ltd, 
Nottingham, U.K.) was applied to the grip of the FMT and the long process of 
the incus without coming into contact with the stapes1. The postoperative 
course was uneventful. Postoperative audiometric evaluation showed an 
negligible air-bone gap of approximately 7 dB (0.5 to 4 kHz) in the right ear. 
The aided hearing levels with the VSB improved to approximately 20 dB HL in 
the midfrequencies (Figure 1A). Over time, the hearing loss in the right ear 
deteriorated gradually from 55 to approximately 100 dB HL, whereas the air-
bone gap increased to more than 30 dB (Figure 1B). Sound-field audiometry 
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showed very poor aided hearing thresholds, and the speech perception score in 
quiet dropped to 0% at 65 dB sound pressure level (SPL). Six years after initial 
FMT implantation of the VSB, exploratory tympanotomy was performed on the 
right ear. The long process of the incus was found to have necrosed, and the 
FMT had migrated into the hypotympanum, which explained the increased air-
bone gap. Unfortunately, the existing FMT was slightly too long to fit on top of 
the stapes head. In addition, the gold-silicon wire that formed the electric 
connection between the FMT and the receiver had retracted posteriorly. 
Therefore, it was decided to place the FMT, after removing the grip, anterior to 
the stapes head, on top of the anterior crus. It was fixed adequately with 
SerenoCem® (SerenoCem®; Corinthian Medical Ltd). A slice of cartilage from the 
medial part of the tragus was interposed between the tympanic membrane and 
the other side of the FMT to avoid extrusion of the FMT. After revision surgery, 
audiometric evaluation showed aided hearing thresholds of approximately 45 dB 
HL. In addition, the air-bone gap was reduced from 35 dB to approximately 25 
dB (0.5-4 kHz; Figure 1C). This is caused by the (passive) FMT, which works as a 
partial ossicular replacement prosthesis. The aided phoneme score in quiet at 65 
dB SPL measured with the right ear was 70%. At present, after a follow-up of 26 
months, aided and unaided hearing thresholds are unchanged, which suggests a 
stable positioning of the FMT. 
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Figure 1A. Hearing thresholds shortly before the initial procedure and aided thresholds 2 months 
after VSB fitting. ac indicates air conduction; AD, right ear; AS, left ear; bc, bone conduction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1B. Hearing thresholds 6 years after the initial procedure, that is, a few months before 
revision surgery. ac indicates air conduction; AD, right ear; AS, left ear; bc, bone conduction. 
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Figure 1C. Hearing thresholds and aided thresholds 1.5 years after revision surgery, with the FMT 
applied as an active partial ossicular replacement prosthesis. ac indicates air conduction; AD, right 
ear; AS, left ear; bc, bone conduction. 
 
Main Outcome Measures 
  
To assess the capacity of this VSB application in which the FMT was interposed 
between the stapes and tympanic membrane, we determined the maximum 
functional gain. When an air-bone gap is present, the functional gain is defined 
as the difference between the (unaided) bone-conduction thresholds and the 
aided soundfield thresholds. Thus, the size of the air-bone gap does not 
influence the calculated functional gain of the VSB. Furthermore, functional 
gain has only been defined for linear devices. Therefore, to measure the 
capacity of the VSB, it was programmed in linear amplification mode. Noise 
reduction and speech enhancement functions were switched off and the output 
of the VSB was not limited (volume at maximum). Aided soundfield thresholds 
were determined with warble tones at frequencies of 250 Hz to 8 kHz, presented 
by a loudspeaker placed 1 metre in front of the patient in a sound-treated 
double-walled room. The patient in the present report underwent these 
measurements for the first time as part of a published study on the gain and 
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maximum output of middle ear implants after her VSB had been applied in the 
conventional manner2. These measurements were repeated 9 months after 
revision surgery, using the same protocol and VSB audio processor. 
In the previous study, input-output performance of the VSB was also studied by 
measuring SPLs produced in the ear canal. Then, FMT vibrations reach the 
tympanic membrane in reverse and are radiated as sound into the ear canal via 
the tympanic membrane. These SPLs can be recorded in the ear canal with a 
probe-tube microphone2. They depend on several local acoustic factors such as 
open or occluded ear canal, position of the probe-tube microphone, etc. 
Therefore, when a series of values are available during follow-up it is not 
worthwhile to judge the separate SPLs in detail, but they can be used in a 
relative sense. Repeated input-output measurements were performed with the 
VSB set in the linear amplification mode. A well-calibrated frequency sweep 
from 250 Hz to 8 kHz was used as stimulus and presented at levels of 40 to 70 
dB SPL in successive measurements. Sound pressure levels were recorded in the 
occluded ear canal with the Aurical REM system (Madsen, Copenhagen, 
Denmark). This equipment was also used to generate the frequency sweeps2. The 
SPLs on these recordings were plotted as a function of the stimulus level at 
octave frequencies of between 0.5 kHz and 2 kHz. Input-output measurements 
were obtained on the same days as the maximum functional gain measurements.   
 
Results  
 
Figure 2A shows the maximum functional gain measurements versus the 
stimulus frequency with the classical FMT application and with the FMT in direct 
contact with the stapes after revision surgery. Maximum functional gain was 
highest at the midfrequencies, as has been reported before2. Remarkably, the 2 
curves had a comparable shape, which suggests that the 2 FMT-ossicular chain 
couplings have the same power. Therefore, the presence of contact between the 
tympanic membrane and the cartilage complex after revision surgery did not 
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compromise the function of the FMT. However, the positions of the two curves 
were shifted over the frequency axis, which suggests that the 2 FMT-ossicular 
chain couplings have different resonance frequencies. The new application of 
the FMT directly connected to the stapes provided less high-frequency gain but 
more low-frequency gain than the classical application. 
Figure 2B shows the input-output data at 1 kHz. Linear growth was present up 
to an input level of 60 dB SPL. Beyond that level, the slope of the curve 
deviated from the linear growth curve (45-degree line), and the output levelled 
off. The figure shows that the outputs from the 2 FMT applications levelled off 
at similar points. Comparable trends were seen in the evaluations carried out at 
0.5, 1.5 and 2 kHz (data not shown).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2A. Maximum functional gain curves obtained from the 2 VSB applications. 
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Figure 2B. Input-output curves obtained at 1 kHz with the 2 VSB applications. 
 
Conclusions  
 
The FMT of the VSB could be applied successfully to the isolated and mobile 
stapes, whereas the tympanic membrane remained in its normal anatomical 
position. There was significant reduction in the air-bone gap after interposing 
the FMT to reconstruct the ossicular chain. However, the aided hearing 
thresholds were somewhat poorer than those measured after the initial 
procedure (see Figures 1A and 1C). Therefore, in patients with an intact 
ossicular chain, classical application of the FMT to the long process of the incus 
can be considered better than to the head of the stapes. Our new application 
widens the opportunities to fit a VSB in patients without an incus. 
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Abstract 
 
Objective: To determine long-term benefit of the Vibrant Soundbridge (VSB) 
middle ear implant in patients with severe mixed hearing loss and to compare it 
with other hearing devices  
 
Design: A retrospective analysis. 
 
Patients: Six patients with severe mixed hearing loss and a mean sensorineural 
hearing loss component between 40 and 70 dB  
 
Interventions: Patients received a VSB with the Floating Mass Transducer (FMT) 
coupled to the round window or to the oval window via a residual stapes 
structure. 
 
Main outcome Measures: Functional gain and speech recognition results. 
Results are compared to two control groups matched for mean sensorineural 
hearing loss: (1) patients with mixed hearing loss and a bone-anchored hearing 
device and (2) patients with sensorineural hearing loss and traditional 
implantation of the VSB.    
 
Results: There is large variance in functional gain between the patients 
suggesting high variability in the effectivity of the FMT coupling. The speech 
recognition results for the experimental group were not systematically better 
than in either control group.  
 
Conclusions: There is large variability in results that might be ascribed to 
coupling effectivity. On the average, speech recognition results were not better 
or worse than those found in patients with similar hearing loss fitted with 
bone-anchored hearing devices. 
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Introduction 
 
For patients with a severe mixed hearing loss, amplification with a conventional 
acoustic hearing aid is difficult because the device has to “compensate” for 
both the air-bone gap and (part of) the sensorineural hearing loss component. 
A powerful device that could do this may have drawbacks such as feedback 
problems and output saturation. Indeed, when studying patients with a mixed 
hearing loss, Mylanus et al.1 showed that results in terms of speech recognition 
deteriorated with an increase in the air-bone gap. They showed that using a 
bone-conduction hearing aid is the better option as its performance is 
independent of the size of the air-bone gap. Recently, de Wolf et al.2 compared 
within subjects results obtained with a Bone-Anchored Hearing Device (BAHD, 
e.g. the Baha; an effective bone-conduction hearing aid3) with those obtained 
with state-of-the-art behind-the-ear device. They reported better results with 
the Baha system, especially in patients with an air-bone gap exceeding 35 dB2. 
However, a BAHD system has limitations; Bosman et al.4 showed that the most 
powerful BAHD (the Baha Cordelle) has a maximum functional gain (difference 
between bone-conduction thresholds and aided thresholds) of 25 to 30 dB in 
the higher frequencies and 10 to 15 dB in the lower frequencies. This suggests 
that other amplification options need to be considered for patients with severe 
mixed hearing loss. 
Colletti et al.5 used the Vibrant Soundbridge (VSB) active middle ear implant in 
a new surgical configuration for patients with mixed hearing loss. In 7 patients 
with a mild-to-moderate sensorineural hearing loss component, the cochlea was 
directly stimulated by placing the vibrating transducer of the VSB middle ear 
implant, the so-called floating mass transducer (FMT), in an enlarged round 
window niche. Therefore, also with this solution, the air-bone gap is surpassed. 
When the improvement in hearing thresholds (bone-conduction thresholds 
minus the aided thresholds, averaged over the frequencies of 0.5, 1, 2 and 4 
kHz) is calculated from Colletti’s data, values up to 30 dB were found. The 
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authors reported no extrusions or complications in a group of 19 patients 
during a 3-year follow-up period6. From their results, the authors concluded that 
round-window application of the VSB is a good option in patients with mixed 
hearing loss and a sensorineural hearing loss component of up to 60 dB. Since 
the first paper by Colletti and associates, several other papers have published 
promising results on the application of the VSB middle ear implants in patients 
with a mixed hearing loss7-14. Debate continues on the optimal placement of the 
FMT for these patients with regard to FMT fixation location and coupling to the 
round window15-17. In addition, if the stapes is still intact, it is not yet obvious 
whether the FMT should be connected either to the stapes or coupled to the 
round window membrane12,18,19.  
In the period 2006 to 2008, six patients with severe mixed hearing loss received 
a VSB with the FMT connected to the (isolated) stapes or placed in the round 
window niche at our department. This report presents their results.   
More specifically, the aim of the study was to measure gain and output of the 
VSB application and speech recognition scores in these patients with severe 
mixed hearing loss. For matters of comparison, data of two control groups are 
used. Group 1 comprised patients with mixed hearing loss and a sensorineural 
hearing loss component in the same range as that of the experimental group 
fitted with the most powerful BAHD. Group 2 comprised patients with 
traditional VSB middle ear implants (FMT connected to the incus) with pure 
sensorineural hearing loss in the same order of magnitude as the sensorineural 
hearing loss components of the patients in the experimental group. The 
performance of both these control groups have been previously reported20,21.  
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Materials and Methods 
 
Patients 
Between 2006 and 2008, six patients with severe mixed hearing loss received a 
VSB semi-implantable middle ear implant (Med-El Hearing technology, 
Innsbruck, Austria) with the FMT connected directly to one of the cochlear 
windows. The inclusion criteria were as follows: severe-to-profound mixed 
hearing loss with a mean sensorineural hearing loss component between 40 and 
70 dB HL, contraindication for conventional solutions, and no option for 
traditional attachment of the FMT. In four patients, the FMT was connected with 
its clip to the remains of the stapes supra structure. In the two remaining 
patients, one FMT was placed in the enlarged round window niche, and in the 
other patient, the FMT was interposed between the stapes and tympanic 
membrane22. An overview of the patient characteristics (viz. age, degree of 
hearing loss of either ear, middle ear status of the implanted ear, and type of 
FMT coupling) is presented in Table 1. 
 
 
  
 Implanted ear Nonimplanted ear 
Patient Age  
 
Middel  
ear status 
PTAbc 
(dB HL) 
PTAac  
(dB HL) 
Position 
FMT 
PTAbc  
(dB HL) 
PTAac  
(dB HL) 
1 67 Subtotal 
petrosectomy 
45 92 Stapes,  
abdominal fat 
37 43 
2 73 Subtotal 
petrosectomy 
50 98 Round window, 
abdominal fat 
50 92 
3 57 Chain 
disruption 
65 82 Stapes with chain 
reconstruction 
60 70 
4 55 Subtotal 
petrosectomy 
63 115 Stapes, 
abdominal fat 
>65 >110 
5 67 Chain 
disruption 
63 75 Stapes 60 60 
6 70 Chain 
disruption 
70 102 Stapes, 
interposition 
53 53 
 
 
 
Ac indicates air conduction; bc, bone conduction; PTA, mean hearing threshold at 0.5, 1 and 2 kHz 
of the implanted ear. 
 
 
 
 
 
 
Table 1. Overview of patients’ characteristics. 
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Patient 1 had symmetric sensorineural hearing loss and a unilateral air-bone 
gap (right ear) owing to a radical cavity because of a long history of otorrhea. 
At presentation in our clinic, the cavity was covered with inflamed mucosa. A 
BAHD on a headband had been previously fitted on the right side, but its 
benefit was insufficient. In addition to the sensorineural hearing loss, the 
patient had recurrent external otitis of the right ear. Therefore, this patient was 
not a candidate for an acoustic hearing aid and a VSB was inserted in a two-
stage surgical procedure. The first procedure consisted of a subtotal 
petrosectomy with placement of abdominal fat. Three months later, the VSB was 
implanted with the clip of the FMT coupled to the stapes suprastructure in such 
a way that the FMT vibrated in parallel with the natural movement of the 
stapes. 
Patient 2 had bilateral mixed hearing loss with a severe sensorineural hearing 
loss component and used the most powerful BAHD, the Baha Cordelle (Cochlear 
BAS, Göteborg, Sweden) because of recurrent otorrhea. Since placement of the 
titanium implant for BAHD application, the sensorineural hearing loss 
component had deteriorated, and speech perception with this device was no 
longer satisfactory. For this reason, a VSB was implanted in the worst ear 
(contralateral to the BAHD  aided ear). During the surgical procedure, a subtotal 
petrosectomy was performed because of inflamed mucosa of the middle ear. The 
FMT was placed in the enlarged round window niche as the incus was found to 
be absent, and the stapes footplate was immobile. A small piece of Tutopatch® 
(Tutogen Medical GmbH, Neunkirchen am Brand, Germany) was placed between 
the round window membrane and the FMT. At the end of the procedure, the 
petrosectomy cavity was filled with abdominal fat.  
Patient 4 had severe mixed hearing loss and radical cavities in both ears 
because of cholesteatoma. The patient had been fitted with a Baha Cordelle; 
however, the BAHD has not been able to adequately amplify sounds due to a 
deteriorating sensorineural hearing loss component. Eight years after BAHD 
application, a VSB was implanted in the ear contralateral to the BAHD aided 
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ear. During surgery, only the stapes was identified and found to be mobile. The 
FMT was connected to the stapes suprastructure so that it moved in parallel to 
the natural stapes movement. The radical cavity was then filled with abdominal 
fat.  
The remaining three patients (Patients 3,5 and 6 in Table 1) had bilateral 
moderate-to-severe sensorineural hearing loss and therapy-resistant chronic 
external otitis. These patients had been previously implanted with a VSB in the 
traditional manner. At some stage after implantation, the air-conduction 
thresholds in the implanted ears had deteriorated, whereas the bone-conduction 
thresholds had not changed. During an exploratory tympanotomy, all three 
patients had necrosis of the long process of the incus. The FMT was therefore 
replaced and connected to the stapes. In patient 3 and patient 5, the clip of 
the FMT was attached around the stapes head so that the FMT could move 
parallel to the natural movement of the stapes. In patient 6, the FMT could not 
be clipped with sufficient strength to the stapes. Therefore, the FMT was 
attached with SerenoCem® (Corinthian Medical Ltd, Nottingham, UK) anterior to 
the stapes head on top of the anterior crus. Furthermore, a slice of cartilage 
from the medial part of the tragus was interposed between the tympanic 
membrane and the other side of the FMT to avoid extrusion of the FMT22.  
All subjects were fitted with the VSB 404 audio processor (Med-El, Innsbruck, 
Austria) four weeks after surgery. The audio processors were fine-tuned during 
follow-up sessions, and the noise reduction and speech enhancement algorithms 
were deactivated. Sound quality of the audio processors was regularly assessed 
by connecting the audio processor to a so-called ‘implant-in-the-box’ (Med-El, 
Innsbruck, Austria). 
Audiometry was performed using standard equipment and standard procedures. 
Aided thresholds were measured using calibrated warble tones generated by an 
audiometer (modulation frequency of 5%) presented via a loudspeaker placed 1 
m in front of the patient. The contralateral ear was occluded with an earplug 
and earmuff during sound field testing.  
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Two speech audiometry scores were used to determine aided speech recognition 
in quiet: phoneme recognition score at 65 dB SPL presentation level (PS65)20 
and aided speech reception threshold (SRT). Standard word lists comprising 11 
phonetically balanced CVC words23 were presented in the sound field. Phoneme 
recognition was scored and the mean score per list was determined. Mean 
phoneme score was determined as a function of presentation level. This results 
in so-called free-field speech audiograms. The SRT is the shift in presentation 
level (compared with normal-hearing subjects) at which aided speech 
recognition score is 50%. If the patient was unable to attain a score of 50%, 
the SRT at 25% correct phoneme recognition was used. PS65 and SRT 
measurements were repeated in the follow-up period. The change in speech 
recognition scores over time was tested on significance, according to Thornton 
and Raffin24. 
As the audio processors make use of adaptive amplification, gain is input 
dependent. Therefore, we refer to functional gain as ‘the functional gain at 
threshold level’.  
Measurements were taken after several fine-tuning sessions (minimum of two 
sessions) with an acclimatization period of at least 6 weeks. 
To assess the capacity of the VSB in its nontraditional application, we 
determined the maximum functional gain, which we defined as the difference 
between the bone-conduction thresholds and the aided sound-field thresholds 
while the audio processor was temporarily programmed to linear amplification 
mode and set at its maximum. The output of the devices was unlimited. This 
enabled a patient-independent comparison of coupling effectivity.  
 
Control groups 
Previously presented data from two other studies were used for comparison. One 
group comprised 24 unilateral Baha Cordelle users (see Verhaegen et al., 2009)21 
and the other group comprised 22 unilateral VSB users with traditional implant 
insertion (see Verhaegen et al., 2008)20. The age range for the BAHD control 
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group was 46 to 70 years, and the mean sensorineural hearing loss component 
at 0.5, 1 and 2 kHz ranged from 40 to 75 dB HL. The second control group 
comprised VSB middle ear implant users with pure sensorineural hearing loss 
where the VSB had been inserted in the traditional manner. The age range for 
the control VSB group varied between 34 and 70 years and the mean 
sensorineural hearing loss was between 50 and 70 dB HL. For all patients in the 
control groups, patient selection was the same (see Verhaegen 200820 and 
Verhaegen 200921 for details), and for both groups PS65 scores were available. 
PS65 scores were obtained in the same way as described in this study for the 
experimental VSB group.  
Verhaegen et al. used curve fitting techniques to describe the relation between 
speech recognition at conversational level and the degree of the sensorineural 
hearing loss (component). These data are used for reference purposes. 
 
Results    
 
The postoperative audiometric results are summarized in Table 2. The average 
‘functional gain at threshold level’ (averaged at 0.5, 1 and 2 kHz) varied 
between almost 0 and 28 dB (Table 2, column 3). The initial PS65 score, 
obtained between 2 and 6 months after device fitting, also showed a wide range 
(Table 2, column 4). Except for patient 3, the aided SRTs were rather 
comparable among the patients (around 38 dB, see column 5). From the first 
fitting onwards, patient 3 was dissatisfied with the results: for this patient, the 
gain had to be set to its maximum and resulted in distorted sounds. Therefore, 
this patient stopped using the device. 
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 First Fitting Short-term speech 
scores 
Long-term speech scores 
Patient PTA FF 
(dB HL) 
Gain 
(dB) 
PS65 
(%) 
Aided SRT 
(dB) 
PS65 
(%) 
Aided SRT 
(dB) 
1 48 -3 60 42 80 38 
2 53 -3 28 38 0 >50 
3 48 17 20 46 NA NA 
4 45 18 35 40 45 33 
5 47 16 80 38 65 42 
6 42 28 65 35 65 30 
 
FF indicates free field; Gain, functional gain at threshold level, averaged at 0.5, 1 and 2 kHz; NA,  
not available; PS65, phoneme score at 65 dB SPL; PTA, mean hearing threshold at 0.5, 1 and 2 kHz; 
SRT, the speech reception threshold. 
 
 
 
 
Table 2. Overview of postoperative results.  
 
It was hypothesized that the spread in PS65 scores for the other five patients 
could have been caused by auditory deprivation (the operated ears of patients 
1, 2 and 4 had not been stimulated for several years). To see whether there was 
improvement over time owing to possible perceptual acclimatization, PS65 
measurements were repeated with a follow-up of at least 19 months. Table 2, 
column 6, shows that the PS65 score had changed over time in patients 1, 4 
and 5; however, these changes were not statistically significant. Speech 
recognition in patient 2 had significantly deteriorated as did the aided sound-
field thresholds. Additional testing revealed unchanged unaided bone- and air-
conduction thresholds. Refitting and replacing the audio processor had no 
effect on conduction thresholds. It was concluded that most likely, the FMT was 
no longer properly in place. To date, the patient has refused further surgery. 
Figure 1 shows the best-fit curves for both control groups for PS65 versus the 
sensorineural hearing loss (component). These graphs are reproduced from 
previous studies20,21 (individual data points of the control subjects are not 
shown). In addition, the figure shows the individual PS65 scores of the present 
Long-term results of middle ear implantation for severe mixed hearing loss 
 
 
 
 103 
patients, more specifically, the long-term scores for patients 1, 4, 5 and 6 and 
short-term scores for patients 2 and 3 (nonusers). These PS65 data are also 
plotted as a function of the patient’s individual mean sensorineural hearing loss 
component. When neglecting the data of patients 2 (medical complication) and 
3 (technical complication), the figure suggests that, although the new VSB 
application can compete with the Baha Cordelle, it is not as effective as the 
traditional VSB application.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Individual aided phoneme scores in quiet at 65 dB SPL (PS65) as a function of the mean 
sensorineural hearing loss (0.5, 1 and 2 kHz). Individual patient scores are shown. For comparison, 
best-fit regression curves are shown for two control groups, viz. controls using the Baha Cordelle 
and controls using the VSB middle ear implant in the traditional application mode. 
 
Figure 2 shows the maximum functional gain that was achieved as a function of 
frequency for all the six patients. A large variance is seen and suggests high 
variability in the effectivity of the FMT coupling. The highest gain is generally 
found at 2 kHz and the poorest result is found for the FMT placed in the niche 
of the round window. 
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Figure 2. Individual maximum functional gain as a function of frequency. 
 
Discussion 
 
Hearing aid fitting for patients with mixed hearing loss remains a challenge, 
and there is an ongoing search for the optimal treatment. The application of an 
active middle ear implant in such patients is relatively new, and there are 
questions regarding the long-term stability of the device and the best coupling 
options12,15-18.   
Colletti et al.5 were the first who reported on VSB application in patients with 
mixed hearing loss, and their study reported no long-term complications6. Since 
the first paper by Colletti et al., several other promising reports have been 
published7-14.  
In the present article, we describe the audiometric results of six patients with 
severe mixed hearing loss over a period of 19 months to 4 years after 
implantation. The sensorineural hearing loss components were more severe than 
that of patients described in other studies7-14. In five patients, the FMT was 
connected to the stapes, and in one patient, it was coupled to the round 
window.  
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Figure 1 shows that only patient 6 achieved speech recognition results that 
were comparable to the mean value of the control group of patients with the 
traditional FMT application. The other patients showed worse results. Except for 
patients 2 and 3, however, the PS65 values were close to the best-fit curve of 
the BAHD control group. 
Speech recognition results for patients 1 and 4, those with possibly auditory 
deprivation, did not improve over time (Table 2). The PS65 score of patients 5 
and 6 also did not change significantly over time. 
The PS65 of patient 3 was the lowest, caused by a device-related limitation. The 
audio processor had to be set to its maximum before the patient could hear 
sufficiently. This resulted in distorted sounds, which were verified with the 
‘implant-in-the-box’. These distorted sounds were the reason for the poor 
speech recognition. The problems could not be resolved, and consequently, the 
patients declined further the use of the VSB device.  
Figure 2 presents ‘the maximum functional gain’ (linear amplification mode), 
which can be considered as an indicator of the coupling effectivity. The poorest 
result is found for the patient with the FMT coupled to the round window: a 
negative gain at 0.5 kHz implies that the air-bone gap was not effectively 
surpassed. This result is in accordance with data on coupling effectivity as 
measured in cadavers12,15-17. Several implant groups where the FMT was coupled 
to the round window also reported poor results in the low frequencies5-8. Figure 
2 shows wide variance for the other VSB users where the FMT is coupled to the 
stapes. Differences of up to 30 dB are found. In patients 1 and 4, abdominal fat 
was placed in the subtotal petrosectomy cavity, like in the report by Linder et 
al.8. The curves of these two patients are not distinctive from the other patients 
in our study. In fact, patient 4 had the best gain of all the patients. Zahnert et 
al.12. studied the effectivity of the FMT coupled to the stapes footplate with and 
without filling the middle ear with fluid. They found that the FMT transfer 
function was not significantly reduced. Based on their conclusion and our 
results, we believe that abdominal fat is not a main restrictive factor in 
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coupling effectivity. Therefore, the variations seen in Figure 2 remains largely 
unexplained. It cannot be excluded that learning might have played a negative 
role. To deal with this, intra-operative monitoring was applied to guide the 
surgeon19.    
Although optimization of surgical techniques for FMT placement may improve 
audiological results, individual anatomy considerations will continue to play a 
role in where implants can be located. Use of intraoperative monitoring while 
manipulating the FMT coupling might remain a helpful tool19,25. 
 
Conclusion 
 
For patients with severe mixed hearing loss and contraindication for either the 
use of a conventional hearing aid or for traditional attachment of the VSB, the 
FMT can be directly coupled to the cochlea. This also holds for patients who 
have undergone a subtotal petrosectomy. Our data suggest that for patients 
with severe mixed hearing loss and a sensorineural hearing loss component 
between 45 and 70 dB HL, the VSB with the FMT coupled to one of the cochlear 
windows is a valuable option. The Baha Cordelle might be competitive. Results 
with the VSB might improve if the FMT itself is optimized for this new 
application and/or if the coupling to the cochlea is optimized.   
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Abstract 
 
Objectives: We evaluated 5 patients who were changed over from a Baha 
Cordelle to a cochlear implant (CI). Moreover, the level of phoneme score was 
determined at which a Baha Cordelle user was better helped with a CI. 
 
Methodes: We offer descriptive case reports and a retrospective evaluation of 
speech recognition in Baha Cordelle users and CI users. 
 
Results: In the CI users with noncompromised cochleas, the 10th percentile of 
the aided phoneme score in quiet at 65 dB sound pressure level (PS65) was 
42%. We consider this PS65 as the cutoff level for switching from a Baha 
Cordelle to a CI. When patients with mixed hearing loss were using the Baha 
Cordelle, the PS65 of 42% was obtained at a mean sensorineural hearing loss 
component of about 70 dB hearing level (HL). This 70-dB HL component was 
used to consider Baha Cordelle users for cochlear implantation. The results of 
the 5 patients support these transition criteria. 
 
Conclusions: A CI is a valuable option in patients with mixed hearing loss when 
the sensorineural hearing loss component exceeds 70 dB HL or when the PS65 
with a Baha Cordelle is less than about 40%. In such patients, the implantation 
procedure should be individualized on the basis of the clinical findings in the 
middle ear and mastoid cavity. 
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Introduction 
 
A bone conduction hearing aid is a valuable option for providing sound 
amplification in patients with (predominantly) conductive hearing loss who 
have a congenital aural atresia, or contraindications to the use of ear molds 
that form an essential part of air conduction hearing aids (e.g. recurrent 
otorrhea or therapy-resistant chronic external otitis). There are two types of 
bone conduction hearing aid: conventional devices and bone-anchored hearing 
aid (Baha) systems1,2. Conventional bone conductors comprise a bone 
conduction transducer that has to be pressed firmly against the skull in the 
mastoid region. These devices transmit sounds transcutaneously to the skull. In 
contrast, the Baha system has a transducer that is coupled percutaneously to 
the skull via an osseo-integrated skin-penetrating titanium implant (Figure 1)1,2. 
Experiments have shown that percutaneous transmission of sound vibrations to 
the skull is 10 to 15 dB more efficient than conventional transcutaneous 
transmission3, because the skin and subcutaneous tissues are bypassed.  
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 1. Baha Cordelle. On left is the transducer which, is coupled to the skin-penetrating titanium 
implant. Source: Cochlear Bone Anchored Solutions, AB, Göteborg, Sweden.  
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Today the Baha Cordelle (Cochlear Bone Anchored Solutions, AB, Göteborg, 
Sweden) is the most powerful bone conduction device on the market. Bosman et 
al.4 evaluated the application range of the Baha Cordelle. The upper application 
limits were determined on the basis of the arbitrary choice of an aided speech 
score of at least 50% at 65 dB sound pressure level (SPL). The upper fitting 
limits were calculated as bone conduction thresholds of about 60 dB hearing 
level (HL). However, not all Baha Cordelle patients with a sensorineural hearing 
loss component of up to 60 dB HL achieve optimal hearing results, especially 
when the sensorineural hearing impairment is progressive. Then, a cochlear 
implant (CI) might be a better option after thorough eradication of disease, 
e.g. in case of a draining ear.   
 
In this report, we describe 5 patients in whom a Baha device was replaced by a 
CI. We analyzed their medical histories, hearing thresholds and speech 
recognition scores with the Baha system and later with the CI. In addition, we 
compared the performance of a large group of CI users to that of Baha Cordelle 
users to define the cutoff point at which cochlear implantation is to be 
considered in Baha Cordelle users with progressive hearing loss. 
 
Patients and Methods  
 
At our institute, 5 patients were identified in whom a Baha device was replaced 
by a CI in the past 10 years. Their otologic medical histories and audiological 
results were analyzed.  
To determine when a CI is preferable to the most powerful Baha system (the 
Baha Cordelle)4, we selected a group of 27 experienced Baha Cordelle users and 
2 different groups of experienced CI users from our database. The Baha Cordelle 
subgroup comprised all successive users who were younger than 70 years. 
Patients with a ski-slope sensorineural hearing loss component were excluded, 
viz. patients with a difference in threshold of 35 dB or more between 500 Hz 
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and 4000 Hz. The CI subgroups comprised successive postlingually deaf adults 
younger than 70 years with a multichannel CI implanted between 1998 and 
2004. The first subgroup, group CI-ref, comprised 123 subjects who all had 
noncompromised cochleas (Patients with obliterated or malformed cochleas 
were excluded as well as patients with otosclerosis). The second CI group, CI-
scl, comprised 14 patients with otosclerosis as the cause of deafness, taken 
from a previous study3. The diagnosis of otosclerosis was based on the presence 
of otosclerotic lesions on the preoperative computed tomographic scan, a 
history of stapes surgery, or the finding of fixation of the stapes during the 
surgical implantation procedure. 
In the 3 groups, we analyzed the monaural aided speech recognition scores 
measured in the sound field. Analyses were performed on the aided phoneme 
scores at a presentation level of 65 dB SPL, called the PS65. Phoneme scores 
were obtained with standard lists of 13 phonetically balanced CVC (consonant-
vowel-consonant) words5. The words were presented by a loudspeaker placed at 
1 m in front of the patient. Measurements were performed in a double-walled 
sound-treated booth. In the CI patients, 1-year postimplantation scores were 
used.  
 
Results 
 
Case 1 
A 57-year-old man with otosclerosis presented at our clinic with mixed hearing 
loss, bilateral bone conduction thresholds of approximately 60 dB HL and air-
bone gaps of about 20 dB in the right ear and 50 dB in the left ear. Owing to a 
history of severe, recurrent, therapy-resistant external otitis with conventional 
hearing aids as result of the ear moulds, he was fitted with a Baha Cordelle on 
the right side. With the Baha Cordelle, the mean aided threshold was about 40 
dB HL, while the PS65 was 65%. Over the next 3 years, the patient’s hearing 
deteriorated rapidly and his PS65 with the Baha Cordelle dropped to below 35%. 
Chapter 4 
 
 
 
 116 
It was decided to replace the Baha device with a CI. The aided sound field 
thresholds were about 35 dB HL and the PS65 was 62% 2.5 years after cochlear 
implantation (most recent evaluation; Figure 2). 
 
Case 2 
A 55-year-old man had undergone surgery (canal wall-down) for chronic otitis 
media of his left ear when he was in his thirties. Recently, cholesteatoma 
surgery in his right ear had resulted in complete deafness in that ear. On 
presentation at our clinic, the patient’s left ear showed bone conduction 
thresholds of 60 dB HL and an air-bone gap of about 25 dB, so he was fitted 
with a Baha HC-220 (predecessor of the Baha Cordelle) on the left side. One 
month after Baha implantation, sudden deafness occurred on the left side, and 
the patient received a CI. The CI was placed in the right ear, because of a 
draining cavity on the left side. Because of abnormal anatomy of the cochlea, 
the electrode array could only be partially inserted. A total of 14 electrodes 
were active.. One year after cochlear implantation, the aided hearing thresholds 
were about 40 dB HL and the PS65 was 42%. Five years after cochlear 
implantation, the PS65 was 59% (Figure 2). 
    
Case 3 
A 77-year-old man was totally deaf in his right ear (cause unknown) and had a 
history of cholesteatoma in his left ear, treated with canal wall-down 
mastoidectomy. On presentation at our clinic, the bone conduction thresholds 
were about 50 dB HL, and the air conduction thresholds were about 90 dB HL. 
In addition, the patient had recurrent external otitis. At the age of 68 years, he 
had received a Baha HC-220 on the left side, which resulted in aided hearing 
thresholds of about 40 dB HL and a PS65 of 90%. A progression of hearing loss 
occurred, with deterioration of bone conduction thresholds to about 60 dB HL 
and a PS65 of only 20%. With the somewhat more powerful Baha Cordelle, aided 
hearing thresholds of about 50 dB HL were reached and a PS65 of 58% were 
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reached. Over the next few years, the patient’s hearing deteriorated further to a 
PS65 of 10%. Therefore, at the age of 75 years, it was decided to provide him 
with a CI on the left side. Before cochlear implantation, subtotal petrosectomy 
was performed in a 1-stage procedure, including blind sac closure of the 
external ear canal and occlusion of the eustachian tube. Cochlear implantation 
and obliteration of the mastoid cavity by filling it with abdominal fat, 
completed the procedure. After one year of CI use, his aided hearing thresholds 
were about 40 dB HL, while the PS65 was 83% (Figure 2). Up to now (3 years of 
follow-up), there have been no problems with the CI, or with the obliterated 
middle ear cavity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Monaural aided phoneme scores in quiet at 65 dB sound pressure level (SPL) over years in 
5 patients with Baha Cordelle and later with cochlear implant (CI). Lines connect individual scores. 
Zero point on the horizontal axis is the time of cochlear implantation. To the left of this point, the 
patient was using a Baha Cordelle. Dotted P10-CI line shows 10th percentile of the 65 dB SPL score 
obtained by the CI users with noncompromised cochleas, while the dotted P50-CI line shows the 
median PS65 in the same group. 
 
Case 4 
A 66-year-old man had a history of recurrent otorrhea in the left ear. On the 
right side, he was totally deaf. At the age of 50 years, he presented at our clinic 
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because of unsatisfactory hearing with his conventional bone conductor. 
Audiometry showed bone conduction thresholds of about 50 dB HL and air 
conduction thresholds of about 80 dB HL. A Baha HC-220 was fitted on the left 
side. Postoperative aided sound field thresholds were good at the low 
frequencies (25 dB HL at 250 Hz) but poor at the high frequencies (65 dB HL at 
3 kHz and 100 dB HL at 4 kHz). PS65 was 75%. Over the next few years, the 
patient’s hearing deteriorated. At the age of 59 years, he was almost totally 
deaf. Magnetic resonance imaging showed a cerebellopontine angle tumour on 
the left side, which was removed using a translabyrinthine approach at our 
clinic--a rare approach for that time. Several months later, the cochlear nerve 
was still responding well to electrical stimulation of the round window, so it 
was decided to fit a CI on the left side. Five years later, aided hearing thres-
holds with the CI were about 35 dB HL, while the PS65 was 80% (Figure 2). 
 
Case 5 
A 59-year-old man with otosclerosis had become deaf in his left ear after 
stapedotomy at the age of 24 years. At the age of 52 years, he presented at our 
clinic because his hearing had deteriorated in the right ear. He was also 
suffering from chronic external otitis when the ear was occluded by the ear 
mold of his conventional hearing aid. Audiometry showed bone conduction 
thresholds of about 40 to 60 dB HL for frequencies below 1 kHz and bone 
conduction thresholds of about 70 dB HL for frequencies above 1 kHz; the air 
conduction thresholds were about 105 dB HL, and the PS65 was 0% with his 
current hearing aid. In spite of great sensorineural hearing loss in the 
frequencies above 1 kHz, a Baha Cordelle was fitted on the right side instead of 
a CI, because it was less invasive and less expensive. However, the 
postoperative aided hearing thresholds with the Baha Cordelle were less than 60 
dB HL, and the PS65 was less than 5%. Therefore, shortly afterward, he still 
received a CI on the right side. At the most recent evaluation, 5.5 years after 
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cochlear implantation, the aided thresholds were 30 dB HL, while the PS65 was 
90% (Figure 2). 
 
Comparison of subgroups 
Figure 3 shows the individual PS65 scores in our group of 27 Baha Cordelle 
users, plotted against their individual mean sensorineural hearing loss 
component (at 0.5, 1 and 2 kHz). A regression curve of the second order was 
fitted though the individual data. In the same Figure, the data from the CI-ref 
group are shown. Their phoneme scores were independent of the individual 
levels of hearing loss. Therefore, we calculated the median (p50) PS65 as well 
as the 10th percentile (p10) of the PS65. The p50-PS65 was 74%, whereas the 
p10-PS65 was 42%, these imply that a PS65 of at least 74% was reached by 
50% of the CI-ref group and a PS65 of at least 42% was reached by 90% of the 
CI-ref group.  
In patients with an etiology of otosclerosis, the situation is somewhat different. 
The p50 and p10 values in the CI-scl group were poorer than those in the CI-ref 
group: 45% and less than 10%, respectively.   
 
Discussion 
 
In patients with mixed hearing loss, the most powerful bone conductor on the 
market, the Baha Cordelle, can virtually close the air-bone gap, and in addition, 
it can improve the sensorineural hearing loss component. The 5 patients with 
mixed hearing loss described in this report had first received a Baha system. 
The Baha system was placed in the Nijmegen otorhinolaryngology clinic in all 
the patients except patient 1. However, owing to severe deterioration in the 
sensorineural hearing loss component, the Baha device became ineffective and 
cochlear implantation was the only remaining option. 
In the decision of whether a CI might be preferable to a Baha, it should be 
taken into account that cochlear implantation is more invasive and more 
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expensive and involves greater risk than a Baha treatment. To define 
application criteria for a CI or a BAHA Cordelle, it is therefore more conservative 
to consider the p10-PS65 (42%) as a cutoff point, instead of the p50-PS656. 
Thus, we recommend that a Baha Cordelle might be replaced by a CI when the 
PS65 is less than 42% with the Baha device. Figure 3 shows that the best-fit 
Baha Cordelle PS65 line crossed the p10-PS65 CI line at a mean sensorineural 
hearing loss of between 65 and 70 dB HL. In other words, patients with a mixed 
hearing loss and a mean sensorineural hearing loss component of 70 dB HL or 
higher have speech performances that are generally worse than 90% of the CI 
users with profound sensorineural hearing loss. Therefore, we recommend 
replacing a Baha Cordelle with a CI at a mean sensorineural hearing loss 
component of 70 dB HL (at 0.5, 1 and 2 kHz). However, in patients with rapidly 
progressive hearing loss, the need for cochlear implantation is just a matter of 
time, so it is advisable to implant at an earlier stage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Individual (monaural) aided phoneme scores in quiet at 65 dB SPL (PS65) in Baha Cordelle 
users as function of their mean sensorineural hearing loss component. Best-fit regression curve of 
second order is presented as dotted line. Horizontal P10-CI dotted line shows the 10th percentile of 
65 dB SPL score obtained by the CI users with noncompromised cochleas, and P50-CI dotted line 
shows  median 65 dB SPL score in the same group. HL indicates hearing level. 
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When patients with mixed hearing loss have a modified radical cavity or a 
chronic ear infection, cochlear implantation might be more complicated7. In an 
operated ear, there is always a chance of recurrence or residual disease. 
Besides, in a modified radical cavity, the electrode array might be exposed or 
extruded, even if the array is covered by fascia or cartilage. In patients with 
chronic ear infection, there is a risk of introducing pathogens into the cochlea 
through the cochleostomy opening, which might cause serious side effects. 
Under these circumstances, the procedure should be staged. Initially, these two 
conditions formed contraindications for cochlear implantation8. However, over 
the years, it has been shown that cochlear implantation can be performed 
relatively safely in such patients if the implantation procedure is adjusted9-12. 
In cases 1, 4 and 5, the middle ear was not infected, so cochlear implantation 
could be performed in the classical way. Patients 2 and 3 had a history of 
cholesteatoma followed by surgical eradication. Patient 2 had canal wall-up 
mastoidectomy, which left the anatomy of the middle ear intact, so cochlear 
implantation could be performed in the classical way. Patient 3, in contrast, 
had a history of canal wall-down mastoidectomy. To prevent complications and 
to protect the CI, in this patient cochlear implantation was preceded by 
subtotal petrosectomy, including blind sac closure of the external ear canal and 
occlusion of the eustachian tube in 1 stage. The implantation procedure was 
completed with obliteration of the mastoid cavity.   
After cochlear implantation, all 5 patients showed better aided speech 
recognition scores and better aided thresholds than previously with their Baha 
device (Figure 2). The follow-up (2.5 to almost 6 years) has been uneventful in 
all cases, without any signs of infection around the implant or extrusion of the 
electrode array.  
It should be noted that in patients 1 and 2 the PS65 scores with the CI were 
below the median score in the CI-ref group. In patient 1, this could be 
explained by the underlying otosclerosis, because the PS65 scores in the CI-scl 
group were substantially lower than those in the CI-ref group3. In contrast, the 
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relatively low PS65 in patient 2 might be explained by partial insertion of the 
array, with 14 active electrodes13. 
 
Conclusion 
 
A CI is a suitable option in patients with mixed hearing loss whose 
sensorineural hearing loss component has deteriorated to such an extent that 
their Baha Cordelle is no longer effective. The CI surgery should be 
individualized on the basis of clinical findings in the middle ear and mastoid. In 
general, a CI takes preference over a Baha device in patients with mixed 
hearing loss when the mean sensorineural hearing loss component is 70 dB HL 
or higher or when the PS65 with a BAHA Cordelle is less than about 40%. 
Patients with otosclerosis as the cause of deafness should be counseled that the 
results with a CI might be poorer than those generally found in patients with 
non-compromised cochleas.  
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This thesis presents an overview of the different types of active implantable 
hearing devices available for patients with a hearing loss, with special attention to 
patients who fall within the ‘gray areas’ of device application. Manufacturers of 
implantable hearing aids claim broad indication ranges in terms of hearing loss, 
and as a result audiologic indication ranges overlap between devices. This thesis 
assessed the most suitable hearing rehabilitation options for different patient 
groups. The emphasis lies primarily on audiologic aspects, not on medical aspects 
and cost-effectiveness. A subdivision was made into rehabilitation options for 
patients with sensorineural hearing loss (Chapter 2), patients with mixed hearing 
loss (Chapter 3) and the choice for a Baha bone conduction device or a CI in 
patients with severe mixed hearing loss (Chapter 4).  
 
Sensorineural hearing loss (SNHL) 
 
Conventional acoustic air-conduction hearing aids are the standard (noninvasive) 
hearing rehabilitation option for patients with a SNHL. There are two types of 
conventional hearing aid: an in-the-ear device and a behind-the-ear (BTE) device. 
In chapter 2.1, we described the speech recognition results of patients with a 
state-of-the-art digital BTE hearing aid. The aided phoneme scores at a normal 
conversational level of 65 dB SPL (PS65) were close to the maximum phoneme 
scores measured in unaided condition with headphone. This suggests good speech 
recognition when patients use a BTE device. Results with conventional acoustic 
hearing aids have become better in recent times. We are faced with the problem of 
a moving target: new systems are being developed while existing systems are 
continually being improved. Despite improved BTE device technology and the 
favorable results discussed in chapter 2.1, conventional acoustic hearing aids may 
still provide insufficient benefit for patients with increasing SNHL components.  
Another disadvantage of conventional acoustic hearing devices is that they usually 
occlude the external ear canal. In a number of patients, for example in patients 
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with chronic external otitis, these devices may be contraindicated or impossible to 
fit. Surgery may be a solution for some patients with a narrow external auditory 
meatus and chronic external otitis. Improved aeration and subsequent reduction in 
the frequency of external otitis can be achieved by performing meatoplasty, 
canalplasty or both surgical procedures. If the procedure is successful and the 
frequency of external otitis decreases, a conventional acoustic hearing aid is a 
possible hearing rehabilitation solution. For some patients, the external otitis is 
persistent and resistant to treatment. Furthermore, in some cases the hearing aid 
itself might provoke external otitis (e.g. due to an allergy to the material of the 
ear mold). Even though coating the ear mold with silver or glass may prevent  or 
decrease external otitis in some patients, there remains a group of patients for 
whom conventional acoustic hearing aids are not appropriate. For this group of 
patients, (semi-)implantable hearing aids are a solution. 
In chapter 2.1, we evaluated the results of implantable hearing aids for patients 
with SNHL. In a retrospective study, the speech recognition results of users 
experienced with the Vibrant Soundbridge (VSB), the Otologics middle ear 
transducer (MET) and the cochlear implant (CI) were compared. For middle ear 
implants (MEIs) it has been claimed that sound quality should be superior to 
acoustic devices. A more natural sound is said to be achieved by the direct 
coupling of the hearing device to the middle ear ossicles1. Neither, the speech 
recognition scores in quiet for patients with the VSB nor the Otologics MET were 
superior to those of patients with a state-of-the-art BTE device. This outcome was 
also found in other studies2. When comparing the two MEIs, the speech 
recognition scores, specifically at higher levels of hearing loss, were superior with 
the Otologics MET compared to those with the VSB: an Otologics MET is more 
suitable than a VSB for patients with severe SNHL. For the Otologics MET users, 
speech recognition scores were comparable with those of BTE device users until a 
mean hearing loss of about 75 dB HL; above this level the BTE device users showed 
better speech recognition scores (Figure 1).  
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Figure 1. (adapted from chapter 2.1) The best fitted PS65 lines of the Otologics middle ear transducer 
group, the Vibrant Soundbridge group, and the conventional acoustic hearing aid group. 
 
In cases of profound SNHL, both the MEI and the conventional acoustic hearing 
aid provide insufficient benefit. In these cases, a CI is the option for hearing 
rehabilitation. The surgical procedure required for implanting a CI is an invasive 
procedure compared to that required for a MEI. There is a risk of complete 
irreversible hearing loss associated with the CI procedure for patients with residual 
hearing. In chapter 2.1, the speech recognition (presented as percentile scores at 
p10 and p50) results of patients with a CI were evaluated. The p10 value was 42%, 
which means that 90% of the group of CI users had a speech recognition score 
higher than 42%. A PS65 value of 42% was reached at a mean SNHL of 
approximately 95 dB HL and 85 dB HL for the BTE users and the Otologics MET 
users, respectively. In other words, if the mean SNHL is 95 dB HL or more, 
approximately 90% of the patients would achieve better speech recognition scores 
with a CI than with a BTE and if the mean SNHL is 85 dB HL or more, 
approximately 90% of the patients would achieve better speech recognition scores 
with a CI than with an Otologics MET, if they have a chronic external otitis and 
thus a BTE is not an option. This p10 value was chosen as a transition point to 
switch to a CI. We chose for this conservative value because of the invasive nature 
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of the CI surgery, the irreversibility of the procedure, and the implications for the 
rehabilitation of the patient with a CI. It has to be acknowledged that hearing 
with a CI requires a period of rehabilitation as hearing is based on electrical 
stimulation of the auditory nerve fibers and entails a different way of hearing with 
a different appreciation of natural sounds and music.  
 
Based on differences in speech recognition scores between MEIs and the p10 
transition point for CI recipients, we have designed an application diagram for 
different implantable hearing aids for patients with SNHL (Figure 2). It must be 
realized that such an application diagram depends on the characteristics of the 
MEIs and on the criteria defined for selecting the patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (copied from chapter 2.1) Audiological application criteria for implantable hearing devices for 
patients with sensorineural hearing loss (SNHL) without external otitis. 
 
A BTE device is contraindicated for patients with chronic external otitis. Therefore, 
another application diagram is composed, based on the same p10 transition point 
value for patients with SNHL and chronic external otitis (Figure 3). 
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Figure 3. (copied from chapter 2.1) Audiological application criteria for implantable hearing devices for 
patients with sensorineural hearing loss (SNHL) and external otitis. 
 
Both application diagrams are based on audiology results of patients with flat or 
mildly sloping audiograms, and therefore, are only applicable to patients with this 
kind of SNHL. There are two reasons why it is more difficult to rehabilitate 
patients with abrupt high-frequency SNHL than patients with a flat or mildly 
sloping audiogram by means of a conventional acoustic hearing aid: acoustic 
feedback and the occlusion effect. Acoustic feedback occurs because amplified 
sounds leak out around the ear mold and are then reamplified by the hearing aid. 
The more amplification is applied, the more likely feedback is to occur. Patients 
with sloping high-frequency SNHL have poor high-frequency hearing thresholds 
and require high levels of amplification. A BTE with a fully occluding ear mold 
reduces acoustic feedback but results in the occlusion effect and means that low-
frequency sounds are perceived louder. Ear mold venting lessens the occlusion 
effect but increases the likelihood of acoustic feedback. ‘Open-fit’ conventional 
hearing aids were developed to reduce the occlusion effect as well as acoustic 
feedback. They have an off-the-shelf, open-ear piece positioned in the ear canal 
instead of using a custom-made ear mold. This type of conventional acoustic 
hearing aid provides limited gain in the low frequencies but considerable gain in 
the high frequencies and it is also less predisposing to external otitis than 
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conventional hearing aids with custom-made ear molds. Feedback is minimized by 
rather effective cancelation techniques incorporated in the BTE device. Recently, 
Boeheim et al.3 and Sziklai et al.4 directly compared the VSB and ‘open-fit’ 
conventional hearing aids for patients with predominantly high-frequency SNHL. 
Boheim et al. found poorer speech recognition in quiet as well as in noise for the 
BTE group, whereas Sziklai et al. found no significant difference in speech 
recognition scores for both devices. In other words, unlike in patients with a flat 
or mildly sloping SNHL, it is possible that a VSB might lead to better speech 
recognition than a BTE device for patients with a sloping high-frequency SNHL.  
As mentioned above, it should be noted that the application diagrams are subject 
to change over time as ongoing improvements to acoustic hearing aid technology 
widens the audiometric indication range for BTE devices. This is also applicable to 
the development of MEIs as application criteria might change based on changes to 
surgical implantation techniques and technology. As an example, the recent 
achievements in the preservation of residual hearing in cochlear implantation, 
following the principles of the so-called soft surgery technique are truly amazing5. 
The goal of this technique is to minimize the insertion trauma to the cochlea and 
thereby preserve residual hearing as much as possible to improve CI performance. 
Amongst others, Verhaegen et al. showed that it is possible to preserve residual 
hearing after cochlear implantation using conventional electrodes6. In the last 
decade, the technological development of thinner and shorter electrode arrays has 
given rise to the implementation of CIs in patients with substantial low-frequency 
residual hearing. Preservation of this residual hearing has allowed acoustic 
stimulation of the preserved lower frequencies and electrical stimulation of the 
higher frequencies in the same ear and is called electro-acoustic stimulation (EAS). 
The p10 transition point for CI recipients applies to patients with bilateral 
profound deafness. Incorporating CI recipients with residual hearing into an 
application diagram would have to imply a different approach and a different 
transition point.  
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In addition to the audiological aspects of active implants in patients with SNHL, 
the aspect of cost-effectiveness should be included in the discussion on 
implementing MEIs for hearing rehabilitation. Chapter 2.2 discussed this aspect. 
Effectiveness was assessed by using questionnaires. To calculate cost-
effectiveness, questionnaires were used to determine the utility gain after 
intervention, which was related to the direct cost of treatment. As a matter of 
course, handicap-specific questionnaires are sensitive to problems associated with 
audition and communication; however, most generic health related quality of life 
questionnaires are not. However, only generic questionnaires produce an utility 
score, needed to calculate the cost-effectiveness of an intervention. Therefore, to 
assess cost-effectiveness, in chapter 2.2 the gain in quality of life, assessed from 
handicap-specific questionnaires, was compared to that in CI users. Also the cost 
of middle ear implantation was compared to that of cochlear implantation. The 
assumption in this was that cochlear implantation in postlingually deaf adults is 
cost-effective. The conclusion of this comparison is that implantation of semi-
implantable middle ear devices for patients with SNHL and comorbid chronic 
external otitis can be considered at least as cost-effective as cochlear 
implantation. Middle ear devices are probably not cost-effective for patients with 
SNHL who are just unwilling to accept acoustic devices; however, data are lacking.   
 
Surgical consideration of middle ear implantation 
Although surgical consideration might play a significant role in selecting an 
auditory implant, these aspects have not been considered to date in this thesis. 
We now discuss some of the surgical issues associated with MEI. The VSB can be 
implanted using a transmastoidal posterior tympanotomy approach or a transcanal 
approach. For the transmastoidal posterior tympanotomy approach, the facial 
recess is opened sufficiently to allow insertion of the FMT into the middle ear cleft 
and attachment to the long process of the incus. The conductor link is positioned 
loosely in the mastoidectomy, and a bed is created in the mastoid cortex to place 
the receiver, comparable to cochlear implantation. The transcanal approach was 
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introduced to reduce both the chance of morbidity and the time of surgery. In this 
approach, a retroauricular skin incision is made, followed by preparation of a 
tympanomeatal flap of the skin from the posterior wall of the external auditory 
canal to the middle ear cavity. The bony ear canal is then widened to provide 
sufficient space to manipulate the FMT and a groove is drilled in the postero-
inferior part of the bony external meatus to guide the conductor link. The titanium 
clip of the FMT is manually rotated to enable placement over the lateral surface of 
the distal part of the long process of the incus7. A bony bed is drilled in the 
mastoid cortex to position the receiver of the device. 
Although the transcanal approach is less invasive and faster to perform, it is not 
advocated in patients with external otitis. Zwartenkot et al. reported poor long-
term outcomes with a high number of postoperative complications caused by 
protrusion of the conducting wire through the meatal skin8. 
The surgical procedure for the Otologics MET also involves opening the mastoid 
cavity. After an extended atticotomy, a small hole is made in the incus using a 
laser for insertion of the tip of the transducer probe. The transducer itself is 
anchored onto the cortex of the mastoid. This implantation procedure can be 
hampered by anatomical conditions of the petrous bone. Louvrier et al. described 
some surgical pitfalls, such as a small distance between the incus and the cortical 
mastoid bone or a low middle fossa dura9. Implanting an Otologics MET appears to 
be more complicated than implanting a VSB as coupling the Otologics MET 
transducer to the body of the incus requires high precision and intraoperative 
monitoring of the effectiveness of the coupling is essential. In contrast, the 
coupling of the clip of the VSB transducer to the long process of the incus is 
relatively straightforward. Surgical issues and audiological criteria should be taken 
into account when a patient is eligible for a MEI. 
 
In conclusion, for patients with a moderate to severe SNHL, a conventional 
acoustic hearing aid is the first choice for hearing rehabilitation. For patients with 
a flat or mildly sloping audiogram up to a hearing loss of approximately 75 dB HL, 
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speech recognition with a MEI is comparable to that with a BTE device. For 
patients with chronic external otitis, a BTE device with an occluding ear mold is 
not recommended and instead an open-fit hearing aid might be a better choice. In 
addition to an open-fit hearing aid, meatoplasty and/or canalplasty or a 
dermatological advice could also be of help in treating the external otitis. If, 
despite all of these measures, the patient can still not tolerate a BTE device, then 
a MEI is a good alternative. Based on data acquired with contemporary MEIs, a VSB 
is suitable for patients with mild SNHL up to approximately 65 dB HL and an 
Otologics MET is suitable for patients with mild-severe SNHL up to approximately 
85 dB HL. For patients with severe-profound SNHL, a conventional acoustic 
hearing aid as well as a MEI may still provide insufficient benefit. Then, a CI can 
be considered. 
 
Conductive hearing loss and mixed hearing loss 
 
The hearing rehabilitation options for patients with conductive hearing loss 
depend on the underlying cause of the hearing loss. Patients with conductive 
hearing loss due to sequelae of chronic otitis media may require surgical 
treatment. Patients with active middle ear disease and cholesteatoma formation 
definitely need surgery. For patients with an ossicular chain discontinuity, an 
ossicular chain reconstruction might be considered. Reconstruction might not 
completely restore the hearing loss, for example in patients with a mixed hearing 
loss with a significant SNHL component. Furthermore, it is not always possible to 
close the air-bone gap with reconstructive surgery due to factors such as scar 
formation and compromised aeration of the middle ear. Results of reconstructive 
surgery for hearing may deteriorate with time. For such patients, a hearing aid 
might be fitted. This option is not open to all patients with conductive hearing 
loss. In patients with chronically diseased middle ears a BTE device with an 
occluding ear mold is contraindicated. Sometimes, the ear mold cannot be secured 
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because of the lack of a proficient meatus, or pinna. For these patients, a bone 
conduction device (BCD) is the next option.  
A BTE hearing device is also not a rehabilitation option for patients with 
conductive hearing loss as a result of a congenital aural atresia. Although surgical 
reconstruction of the external meatus is possible, according to Cremers et al. the 
results of such surgery are related to the degree of malformation10. Declau et al. 
advised surgical reconstruction be limited to favorable cases of congenital aural 
atresia where a post-operative hearing of less than 25-30 dB is attainable11. For 
patients where reconstruction was not deemed possible or the results were poor, a 
BCD has frequently been implemented12. 
 
There are two types of BCDs: firstly, conventional or indirect BCDs which transmit 
sounds (as vibrations) transcutaneously to the skull, and secondly, the 
percutaneous or direct BCDs in which the bone-conduction transducer is coupled 
percutaneously to the skull via an osseo-integrated titanium implant. The 
percutaneous BCD was developed to optimize transfer sounds from the amplifier to 
the skull by avoiding the attenuation of the skin and the subcutaneous layers. 
Håkansson et al., the designers of the percutaneous Baha bone-conduction device, 
have shown that percutaneous transmission of sound vibrations to the skull is 10 
to 15 dB more efficient than conventional transcutaneous transmission13. The Baha 
device has been on the market since 1986 and since its release, several Baha 
sound processors with different output characteristics have been developed. For 
patients with mixed hearing loss, a powerful processor is required to compensate 
(partially) for the SNHL component in addition to just ‘closing’ the air-bone gap. 
The Baha Cordelle is the most powerful Baha and is described in chapter 4.  
The surgical implantation procedure of the Baha is possible under local anesthesia 
for adult recipients. A retroauricular longitudinal incision is made at the 
implantation site, 50-55 mm posterosuperiorly to the ear canal on the mastoid. 
The periosteum is mobilized around the screw implantation site. The titanium 
implant is placed in the cortical bone of the mastoid under saline irrigation in a 
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predrilled hole with a depth of 3 to 4 mm. Subsequently, subcutaneous tissue is 
reduced extensively over an area of approximately 2 cm around the implant to 
minimize tissue bulk above and around the screw implantation site14.  
 
A more recent alternative to treat patients with conductive hearing loss or mixed 
hearing loss is to surpass the diseased middle ear by directly coupling a MEI 
transducer and the cochlea. Chapter 3 described how the VSB can be used for 
patients with mixed hearing loss but non-inflamed middle ears and for patients 
treated for chronic ear disease with a subtotal petrosectomy, obliteration of the 
cavity with abdominal fat and a blindsac procedure. The VSB was originally 
developed for patients with an intact ossicular chain. Colletti and co-workers were 
the first to couple the transducer of the VSB, the floating mass transducer (FMT), 
directly to the round window membrane of the cochlea15. Since the first paper by 
Colletti et al., several other papers have been published on this new technique16. 
However, debate remains on the best fixation position and coupling of the FMT for 
patients with conductive or mixed hearing loss. For an intraoperative 
determination of the best fixation and coupling position based on auditory 
thresholds, we used auditory steady state response (ASSR) measurements, see 
chapter 3.1. Although this technique had not been used for such an application, 
it was considered of additional value to guide FMT placement peroperatively in 
individual patients. Until it becomes clear which is the best position of the FMT in 
patients with conductive or mixed hearing loss, we recommend the use of assistive 
intraoperative measurements to determine the best FMT position.  
Chapter 3.2 described a case study in which the FMT of the VSB was attached to 
the stapes. This patient had full incus necrosis after traditional application of the 
FMT because of a pure SNHL and chronic external otitis. The results of the two FMT 
applications (traditional vs. directly to the stapes) were compared and showed 
comparable gain and maximum output; both couplings showed the highest gain in 
the mid-frequencies. In this case, both applications of the FMT proved to be 
equally effective.  
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There are few studies that report long-term results because the technique of 
middle ear implantation in conductive or mixed hearing loss is relatively new. In 
chapter 3.3 we described the long-term audiological results of six patients with 
mixed hearing loss who received a VSB. Two of the patients achieved speech 
recognition results comparable to a reference group of patients who received a 
traditional FMT connection described in chapter 2.1. The other four patients 
showed lower speech recognition results than the reference group. Three of these 
four patients had a long period of auditory deprivation in the implanted ear, which 
could explain the poor results. The speech recognition results in these three 
patients did not improve during the follow up time of at least 19 months. With 
this in mind, we recommend that patients with a long period of auditory 
deprivation be informed before surgery about these possible negative effects. 
Another reason for the non-optimal speech recognition results could be due to a 
technical limitation of the implant which led to underfitting. Two of the six 
patients became non-users owing to insufficient device benefit. The upper 
application range for the new VSB application, as defined by the Med-El company, 
is a SNHL component of 50 dB HL at most (mean at 1, 2 and 4 kHz). This criterion 
was developed for the round window application of the FMT. If we apply this 
criterion to the patients discussed in chapter 3.3, then four of the six patients fall 
outside the criterion. However, five of the six patients had the FMT coupled to the 
(mobile) stapes instead of to the round window. According to the results 
presented in chapter 3.2, the connection of the FMT to the remaining stapes 
structure proved to be as effective as the traditional application of the FMT. This 
suggests that the criterion for stapes application might be the same as that of the 
traditional application, which is, according to the Med-El company, 70 dB HL. 
Thus, the Med-El criterion seems to be too strict for application of the FMT to the 
stapes. Indeed, four of the five patients with the FMT connected to the stapes 
profited from this FMT placement and had adequate speech recognition scores. 
Although several papers have been published on FMT application in patients with 
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mixed hearing loss, the study presented in chapter 3.3 is the only study 
considering FMT use in patients with such a severe SNHL component. 
The speech recognition results of the six patients with mixed hearing loss who 
used MEIs were compared a group of matched patients with mixed hearing loss 
who used Baha Cordelles. The speech recognition scores, when related to the SNHL 
component, were comparable in both groups. We conclude that compared to the 
application of Baha in severe mixed hearing loss, the VSB is a viable alternative. 
Speech recognition might improve if the FMT coupling is optimized for this new 
application or if the VSB has made more powerful. Therefore, in our view, this 
application of the VSB should be considered experimental but promising. Colletti 
et al. reported good stability over 36 months after implantation of the VSB onto 
the round window membrane17. 
In summary, as long as audiological results with a Baha Cordelle in patients with 
mixed hearing loss are comparable to the results of MEI application, one should 
take into account the aspect of the implantation surgery: implantating a Baha is 
less complicated and less time consuming and has a lower risk of complication 
than implantating a VSB. At this moment, a Baha Cordelle might be considered as 
the first option in patients with mixed hearing loss. However, conditions that 
might impede good results of a percutaneous implant may cause the clinician to 
consider a VSB instead. For now, long-term results of application of MEI for mixed 
hearing loss need to be obtained and further knowledge is required on coupling 
efficiency and intraoperative monitoring (i.e. ASSR) before an overall preference 
can be given for one device. 
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Severe mixed hearing loss 
 
Patients with mixed hearing loss and a mild to moderate SNHL component can be 
provided with a BTE device, a powerful BCD, or a powerful MEI. However, these 
options become ineffective as the severity of the SNHL component increases. For 
patients with severe SNHL component, a CI is the only remaining option. Chapter 
4 presented the results of five patients in whom a Baha device was replaced with a 
CI owing to severe deterioration of their SNHL component. As described in chapter 
2.1, the p10-PS65 value was used to determine a transition point for Baha 
Cordelle to CI. Based on our analysis, when the SNHL component exceeds 70 dB 
HL, a CI might be considered as the better option. In these cases, the middle ear 
should be free of infection. A staged surgical procedure may be needed to reduce 
the risk of a CI extrusion or meningitis. 
 
Conclusion 
 
The introduction of active implants in otology has created new possibilities for 
hearing rehabilitation in patients with hearing loss for whom a BTE is not a 
suitable option or effective option. For patients with SNHL, MEIs are a good option 
when chronic external otitis is present whereas BTE devices are the better choice 
when there is no external otitis. For patients with conductive hearing loss or 
mixed hearing loss, the BCD is a good option; although a MEI might also be 
considered for these two groups of patients, MEIs should still be considered an 
experimental option. For patients with profound SNHL, CIs are the current standard 
treatment. Investigating the use of CIs is beyond the scope of this thesis. 
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Summary 
 
This thesis started in chapter 1 with a general introduction in which the 
different types of active semi-implantable hearing aids addressed in this thesis 
are discussed, namely the cochlear implant (CI), the middle ear implant and the 
percutaneous bone conduction device. A CI directly stimulates the acoustic 
nerve via an implanted electrode bundle in the cochlea and is applicable for 
patients with a profound sensorineural hearing loss. The main component of a 
middle ear implant is its implanted transducer, which directly stimulates one of 
the ossicles in the middle ear to amplify sounds and pass them to the inner ear. 
Middle ear implants are developed for patients with a sensorineural hearing 
loss. Currently, there are two commercially available types of (semi-implantable) 
middle ear implants: the Vibrant Soundbridge (VSB) and the Otologics Middle 
Ear Transducer (MET). Both implants connect with the incus in the middle ear 
via a transducer. In 2006, Colletti and colleagues were the first to implant the 
VSB in patients with mixed hearing loss, in which the transducer, called the 
floating mass transducer (FMT), was placed in the round window niche instead 
of being coupled to the incus. This application showed good results and many 
others have adopted this application. Nowadays, it seems that there is a place 
for middle ear implants in patients with conductive hearing loss and in patients 
with mixed hearing loss. A long-standing implant for conductive hearing loss is 
the percutaneous bone conduction device, of which the bone-anchored hearing 
aid (Baha) was the first known and it is still used quite a lot. This implant 
transfers sounds to the cochlea by way of vibrations directly through the skull 
via an implant that is secured to the skull and coupled to a percutaneous 
abutment. However, for most people with a hearing loss, a conventional 
acoustic hearing aid is a good hearing rehabilitation option.     
 
Chapter 2 discussed active implantable hearing aids suitable for patients with a 
sensorineural hearing loss. 
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In chapter 2.1, a retrospective study is discussed in which audiological 
application criteria were created for four types of hearing aids: conventional 
acoustic hearing aids, VSB middle ear implants, Otologics MET middle ear 
implants and CIs. For this study, the aided speech recognition scores at an 
input level of 65 dB SPL (PS65) were studied and related to the degree of 
sensorineural hearing loss. From this, it can be concluded that the speech 
recognition scores with a conventional acoustic hearing aid were certainly not 
worse than that those obtained with both types of middle ear implants. If we 
compare the VSB with the Otologics MET, it is striking that the Otologics MET 
shows higher speech recognition scores at a comparable sensorineural hearing 
loss. As the CI users all have a profound hearing loss or are completely deaf, we 
have not related the speech recognition scores to the sensorineural hearing 
loss, but instead we assessed the group scores. The p10-PS65 score is the score 
that was reached in 90% of the CI users and equals 42%. This score was reached 
in the group of patients with a conventional acoustic hearing aid at a 
sensorineural hearing loss of approximately 95 dB HL and in the group of 
patients with an Otologics MET at a sensorineural hearing loss of approximately 
85 dB HL. Based on these p10-PS65 scores, we composed two audiological 
application diagrams: one for patients with a sensorineural hearing loss and one 
for patients with a sensorineural hearing loss and chronic external otitis. In this 
last patient group, a conventional acoustic hearing aid is contraindicated and 
is, therefore, beyond the scope of the application area.   
Chapter 2.2 discussed the aspect of cost-effectiveness of middle ear implants in 
patients with a sensorineural hearing loss. Four studies on quality of life in 
patients with a middle ear implant were reviewed. From this, it is concluded 
that middle ear implants are just cost-effective in the group of patients with 
sensorineural hearing loss who suffered an additional therapy-resistant external 
otitis and thus cannot use a conventional acoustic hearing aid. 
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Chapter 3 discussed the use of VSB middle ear implants in patients with a 
mixed hearing loss. This is a relatively new application and there is still debate 
on the best fixation position and coupling of the FMT in the middle ear. In 
addition to coupling in the round window niche, the FMT can also be coupled, 
for example, to a mobile stapes if this is present. 
In chapter 3.1, a study is described in which intraoperative objective hearing 
thresholds of four patients with a mixed hearing loss and no incus were 
measured while the cochlea was stimulated via the middle ear implant to 
determine the best FMT position. In this study, Auditory Steady State Response 
(ASSR) measurements were used while the FMT position was changed 
intraoperatively. Finally, the position with the best ASSR response was chosen. 
In three out of the four patients, the FMT was coupled to the mobile stapes. In 
one patient, the FMT was coupled to the round window because the stapes was 
fixed. The manner of FMT fixation in the round window niche had no direct 
effect on the ASSR responses, nor the creation of a stapedotomy opening in the 
fixed stapes footplate. 
Chapter 3.2 described a patient who had a traditional VSB application in the 
past due to a sensorineural hearing loss and chronic external otitis. This means 
that the FMT was coupled to the incus in a patient with an intact ossicular 
chain. Over the years, there was a gradual hearing deterioration in the patient’s 
hearing. An interruption in the ossicular chain due to necrosis of the long 
process of the incus meant that the VSB could no longer function sufficiently. 
In this patient, a new VSB was implanted with the FMT interposed between the 
stapes and the tympanic membrane by means of a piece of autologous cartilage. 
The patient’s hearing results with the new VSB were compared with the patient’s 
results taken from when the FMT functioned normally in its traditional position. 
The hearing thresholds measured with the FMT in its new position were 
comparable with the results with the FMT in its traditional position. Both the 
speech recognition results and the maximum functional gain were comparable in 
both situations. In addition, the maximum output was also measured. This has 
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shown that in both FMT applications, the output seems to be limited at the 
same input level. Hence, this chapter also shows that application of the VSB in 
patients with a mixed hearing loss is a good possibility.     
Chapter 3.3 presented the retrospective long-term results of six patients with a 
severe mixed hearing loss in which the VSB was implanted with the FMT fixed to 
the stapes or in the round window niche. Four out of the six patients were 
described in chapter 3.1. In five patients, the FMT was coupled to the stapes 
and in one patient the FMT was coupled in the round window niche. The 
maximum functional gain as well as the postoperative speech recognition scores 
(PS65) showed wide variation between patients. This variation could be 
attributed to the high variability in the effectiveness of the FMT coupling. The 
highest gain was found at a frequency of 2 kHz in all the six patients; the round 
window coupling showed the poorest result. The PS65 scores of the six 
implanted patients were compared with the PS65 scores of matched patients 
from two groups: patients with mixed hearing loss who used the most powerful 
percutaneous bone conduction device (Baha Cordelle) and patients with a pure 
sensorineural hearing loss in which the VSB was implanted with the FMT in its 
traditional position (i.e. coupled to the long process of the incus). The scores 
of the six patients with the new FMT application are somewhat below the scores 
of the group of patients with the traditional FMT application. Four out of the six 
patients have comparable scores with the group of patients with a percutaneous 
bone conduction device, the Baha Cordelle. The two other patients have low 
PS65 scores due to medical and technical complications. 
 
Chapter 4 described five patients with a severe mixed hearing loss who changed 
from a Baha Cordelle device to a CI due to deteriorations in sensorineural 
hearing. Directly after the first fitting of the CI, all the six patients scored 
better than they did preoperatively with their Baha Cordelle. Because of chronic 
otitis media, in some patients a subtotal petrosectomy, obliteration of the 
cavity with abdominal fat and a blindsac procedure had to be done before 
Summary | Samenvatting 
	   153 
cochlear implantation. In this chapter, an audiological criterion was sought at 
which it is justified to switch from a Baha Cordelle to a CI. A retrospective 
analysis was done on the aided PS65 scores in a group of Baha Cordelle patients 
and in a group of CI patients. The group of CI patients is the same as that in 
chapter 2.1. As it discussed in chapter 2.1, the p10-PS65 score in this group 
was 42%. As in chapter 2.1, this score was chosen as a transition point to 
switch from one implant to another. In the Baha Cordelle group, a PS65 score of 
42% was reached at a sensorineural hearing loss component of 70 dB HL. This 
means that at a sensorineural hearing level component of 70 dB HL or more, it 
is justified to switch from a Baha Cordelle to a CI. The results of the five 
patients confirm this. However, it has to be acknowledged that switching to a 
CI is a large transition in terms of irreversibility as well as the required 
rehabilitation. The rehabilitation process requires a great deal of effort by the 
patient because the patient has to learn how to interpret the new electrical 
stimulation of the acoustic nerve.  
      
Chapter 5 described a general discussion on the complete thesis along with a 
summary of each chapter’s conclusions.   
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Samenvatting 
 
Dit proefschrift begint in hoofdstuk 1 met een algemene inleiding, waarin de 
diverse types actieve semi-implanteerbare gehoor-implantaten worden 
besproken die in dit proefschrift aan bod komen, te weten een cochleair 
implantaat (CI), een middenoorimplantaat en een percutaan 
beengeleidingstoestel. Een CI stimuleert rechtstreeks de nervus acousticus via 
een geïmplanteerde electrodebundel in het slakkenhuis en is toepasbaar voor 
patiënten met een zeer ernstig perceptief gehoorverlies. Een 
middenoorimplantaat heeft als belangrijkste onderdeel een geïmplanteerde 
transducer die rechtstreeks een van de gehoorbeentjes in het middenoor 
stimuleert om zo het geluid versterkt te kunnen doorgeven aan het binnenoor. 
Middenoorimplantaten zijn ontwikkeld voor patiënten met een perceptief 
gehoorverlies. Momenteel zijn er twee typen (semi-implanteerbare) 
middenoorimplantaten commercieel beschikbaar: de Vibrant Soundbridge (VSB) 
en de Otologics Middle Ear Transducer (MET). Allebei maken ze via hun 
transducer contact met de incus in het middenoor. In 2006 hebben Colletti en 
collega’s de VSB voor het eerst toegepast bij patiënten met gemengde 
gehoorverliezen, waarbij de transducer, de zogenoemde floating mass 
transducer (FMT), werd geplaatst in de ronde vensternis in plaats van gekoppeld 
aan de incus. Deze toepassing toonde goede resultaten en velen hebben dan 
ook deze toepassing overgenomen. Zo lijkt er tegenwoordig ook een plek voor 
de middenoorimplantaten bij patiënten met conductieve en gemengde 
verliezen. Een al langer bestaand implantaat voor de conductieve 
gehoorverliezen is de percutane beengeleider, waarvan de bone-anchored 
hearing aid (Baha) het eerst op de markt was en nog steeds veel wordt 
toegepast. Dit implantaat geeft via een implantaat in de schedel, met daarop 
een percutaan koppelstuk, geluiden in de vorm van trillingen rechtstreeks door 
aan de schedel waardoor de cochlea gestimuleerd wordt. Echter, voor de meeste 
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patiënten met gehoorverliezen geldt, dat een conventioneel akoestisch 
hoortoestel tot goede gehoorrevalidatie leidt. 
 
In hoofdstuk 2 werden actieve gehoorimplantaten besproken welke geschikt 
zijn voor patiënten met een perceptief gehoorverlies.  
In hoofdstuk 2.1 werd een retrospectieve studie besproken, van waaruit 
audiologische toepassings criteria zijn opgesteld voor de diverse typen 
hoortoestellen: conventioneel akoestische hoortoestellen, VSB 
middenoorimplantaten,  Otologics MET middenoorimplantaten en CIs. De 
geholpen spraakverstaan scores bij een input level van 65 dB SPL (PS65) werden 
hiertoe bestudeerd, gerelateerd aan de mate van perceptief gehoorverlies. 
Hieruit kan worden geconcludeerd dat de spraakverstaan scores met een 
conventioneel akoestisch hoortoestel zeker niet slechter zijn dan die van beide 
typen middenoorimplantaten. Als we de VSB vergelijken met de Otologics MET, 
dan valt op dat de Otologics MET hogere spraakverstaanscores laat zien bij een 
vergelijkbaar perceptief gehoorverlies. Aangezien de CI gebruikers allemaal zeer 
slechthorend tot volledig doof zijn, hebben we in deze patiëntengroep de 
spraakverstaanscores niet gerelateerd aan het perceptieve gehoorverlies, maar 
hebben we gekeken naar groepsscores. De p10-PS65 score is de score die in 90% 
van de CI gebruikers wordt gehaald en is gelijk aan 42%. Deze score wordt in de 
patiëntengroep met een akoestische conventioneel hoortoestel behaald bij een 
perceptief gehoorverlies van ongeveer 95 dB HL en in de patiëntengroep met 
een Otologics MET bij een perceptief gehoorverlies van ongeveer 85 dB HL. Op 
basis van deze p10-PS65 scores werden twee audiologische 
toepassingsdiagrammen opgesteld: een voor patiënten met enkel perceptief 
gehoorverlies en een voor patiënten met een perceptief gehoorverlies en 
chronische otitis externa. In deze laatst genoemde patiëntengroep is een 
conventioneel akoestisch hoortoestel gecontraindiceerd en deze valt dan dus 
ook buiten het toepassingsgebied. 
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In hoofdstuk 2.2 werd ingegaan op het aspect kosteneffectiviteit bij het 
gebruik van middenoorimplantaten bij patiënten met een perceptief 
gehoorverlies. Er werden vier literatuurstudies beoordeeld die allen de kwaliteit 
van leven hebben onderzocht door middel van vragenlijsten bij patiënten met 
een middenoorimplantaat. Hieruit is geconcludeerd dat middenoorimplantatie 
alleen kosteneffectief is in de groep patiënten die naast het perceptieve 
gehoorverlies ook een therapie-resistente chronische otitis externa hebben en 
dus geen conventioneel akoestisch hoortoestel kunnen verdragen.     
 
In hoofdstuk 3 werd ingegaan op het gebruik van VSB middenoorimplantaten 
bij patiënten met een gemengd gehoorverlies. Dit is een relatief nieuwe 
toepassing, waarvan nog weinig duidelijkheid bestaat over de beste fixatie en 
beste positie van de FMT in het middenoor. Naast koppeling in de ronde 
vensternis, zou de FMT bijvoorbeeld ook gekoppeld kunnen worden aan een 
mobiele stapes, als deze aanwezig is.  
In hoofdstuk 3.1 werd een studie beschreven waarin bij vier patiënten met een 
gemengd gehoorverlies zonder aanwezigheid van een incus, intraoperatieve 
objectieve gehoordrempelmetingen zijn verricht voor bepaling van de meest 
optimale FMT positie, terwijl het slakkenhuis werd gestimuleerd via het 
middenoorimplantaat. Er is in deze studie gekozen voor het gebruik van 
Auditory Steady State Response (ASSR) metingen, terwijl de FMT positie 
intraoperatief gewisseld werd. Voor de positie met de beste ASSR respons werd 
uiteindelijk gekozen. In drie van de vier patiënten bleek de FMT het beste te 
functioneren bij koppeling aan de mobiele stapes. In een patiënt was de stapes 
gefixeerd en werd gekozen voor een ronde venster koppeling. De wijze van 
fixatie van de FMT in de ronde vensternis had geen direct effect op de ASSR 
responsies, evenmin het maken van een stapedotomie opening in de gefixeerde 
voetplaat.  
In hoofdstuk 3.2 werd een patiënt beschreven die in het verleden vanwege 
perceptief gehoorverlies en chronsiche otitis externa een klassieke VSB 
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toepassing heeft gehad. Dat wil zeggen, een FMT koppeling aan de incus bij een 
patiënt met een intacte gehoorbeenketen. In de loop van de jaren trad bij deze 
patiënt geleidelijke verslechtering op van het gehoor. Dit bleek te berusten op 
onderbreking van de gehoorbeenketen ten gevolge van necrose van het lange 
been van de incus, waardoor de VSB niet meer voldoende kon functioneren. Bij 
deze patiënt werd een nieuwe VSB geplaatst, met koppeling van de FMT aan de 
stapes enerzijds en aan het trommelvlies anderzijds via een stukje autoloog 
kraakbeen. De resultaten op het gehoor werden vergeleken met de resultaten 
die patiënt behaalde met de FMT in de klassieke toepassing, uit de tijd dat deze 
nog normaal functioneerde. De gehoordrempels gemeten met de FMT in de 
nieuwe positie waren nagenoeg gelijk aan die gemeten met de FMT in de 
klassieke positie. De spraakverstaanscores in beide situaties waren vergelijkbaar, 
alsook de maximaal te behalen versterking. Tevens werd de maximale output 
gemeten. Hieruit is gebleken dat bij beide FMT toepassingen de output begrensd 
lijkt te zijn vanaf een zelfde input niveau. Ook dit hoofdstuk laat dus zien dat 
toepassing van de VSB bij een gemend gehoorverlies een goede optie is. 
In hoofdstuk 3.3 werden de lange termijn resultaten weergegeven van 
patiënten met een fors gemengd gehoorverlies waarbij een VSB werd geplaatst 
met FMT op de stapes of in de ronde vensternis. Het is een retrospectieve 
weergave van de resultaten van zes patiënten. Vier van de zes patiënten werden 
beschreven in hoofdstuk 3.1. In totaal werd bij 5 patiënten de FMT gekoppeld 
aan de stapes en bij een patiënt werd de FMT gekoppeld in de ronde vensternis. 
Zowel de maximum functional gain als de postoperatieve spraakverstaanscores 
(PS65) toonde een grote variatie tussen de patiënten onderling, wat te maken 
kan hebben met de grote verschillen in effectiviteit van de FMT-koppeling. De 
grootste versterking wordt bij alle zes de patiënten behaald bij een frequentie 
van 2 kHz, waarbij de ronde vensterkoppeling de laagste waarde laat zien. De 
PS65 scores van de zes geïmplanteerde patiënten werden vergeleken met de 
PS65 scores van twee groepen gematchte patiënten: patiënten met gemengd 
gehoorverlies en het sterkste percutane beengeleidingstoestel (Baha Cordelle) 
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en patiënten met een zuiver perceptief gehoorverlies waarbij de VSB is 
geïmplanteerd met de FMT in de klassieke positie, gekoppeld aan het lange been 
van de incus. De scores van de 6 patiënten met de nieuwe FMT toepassing 
liggen enigszins onder die van de groep met de klassieke FMT toepassing. Vier 
van de zes patiënten hebben scores vergelijkbaar met die in de groep patiënten 
met een percutane beengeleider, de Baha Cordelle. De twee overige patiënten 
hebben lage PS65 scores, wat te wijten valt aan een medische en een 
technische complicatie.  
 
In hoofdstuk 4 werden vijf patiënten beschreven met een zeer groot gemengd 
gehoorverlies. Allen waren in het verleden geïmplanteerd met een Baha Cordelle 
en zijn in de loop van de tijd, vanwege achteruitgang van de perceptieve 
gehoordrempel, voorzien van een CI. Al direct na aanpassing van het CI 
scoorden alle zes de patiënten beter dan dat zij preoperatief deden met hun 
Baha Cordelle. Vanwege chronische otitis media moest in sommige patiënten 
voorafgaand aan de cochleaire implantatie een sanering van het middenoor 
worden verricht, in de zin van een subtotale petrosectomie met opvullen van de 
ontstane holte met buikvet en afsluiten van de buis van Eustachius en 
uitwendige gehoorgang. In dit hoofdstuk wordt gezocht naar een audiologisch 
criterium waarop gerechtvaardigd kan worden geswitcht van een Baha Cordelle 
naar een CI. Hiervoor werd een retrospectieve analyse verricht naar de geholpen 
PS65 scores in een groep Baha Cordelle patiënten en in een groep CI patiënten. 
De groep CI patiënten is dezelfde als die in hoofdstuk 2.1. Zoals daar al werd 
besproken is de p10-PS65 score binnen deze groep 42%. Deze waarde werd, net 
als in hoofdstuk 2.1, gekozen als moment voor overgang van het ene implantaat 
naar het andere. Een PS65 score van 42% wordt in de Baha Cordelle groep 
bereikt bij een perceptieve component van 70 dB HL. Dit betekent dat het vanaf 
deze perceptieve drempel zinvol is om te switchen van een Baha Cordelle naar 
een CI. De resultaten van de vijf patiënten bevestigen dit. Wel moet er rekening 
mee worden gehouden dat de overgang naar een CI groot is, zowel vanwege de 
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onomkeerbaarheid als vanwege de revalidatie die ervoor nodig is. Dit laatste 
vergt voor de patiënt een grote inspanning, omdat deze zal moeten leren 
omgaan met de nieuwe manier van horen, wat veroorzaakt wordt door de 
elektrische stimulatie van de gehoorzenuw. 
 
In hoofdstuk 5 werd een algemene discussie op het gehele proefschrift 
weergegeven met conclusies behorende bij de diverse hoofdstukken.             
 
 
 
Summary | Samenvatting 
	   161 
 
titelpagina_Dankwoord etc.indd   1 17-02-12   09:15
 
Dankwoord
Curriculum Vitae
List of Publications
titelpagina_Dankwoord etc.indd   2 17-02-12   09:15
 
 
 
 
 
 
 
 
 
 
 
 
Dankwoord 
 
 
 
 165 
Dankwoord 
 
Promoveren doe je niet alleen en dat is maar goed ook, want zonder de hulp 
van anderen was dit proefschrift nooit geworden wat het nu is. Een aantal 
mensen wil ik hier dan ook in het bijzonder voor bedanken. 
 
Allereerst professor Snik, mijn eerste promotor. Beste Ad, vanaf de start van 
mijn onderzoek was duidelijk dat jij mijn promotor zou worden. Als ik je tips en 
adviezen nodig had, dan was je er voor me en maakte je tijd voor me vrij. Ons 
overleg was altijd nuttig en productief. Uiteindelijk kan ik wel zeggen dat jij het 
brein bent achter deze promotie. Naast mijn promotieonderzoek ben ik in 2008 
gestart met de opleiding tot KNO-arts. Vanaf dat moment veranderde mijn 
prioriteit en kwam het onderzoek op een lager pitje te staan, wat voor jou niet 
altijd makkelijk moet zijn geweest. Uiteindelijk ben ik blij dat we nu toch samen 
de eindsprint hebben ingezet, met dit boekje als resultaat. Hier mag jij net zo 
trots op zijn als ik. Ontzettend bedankt! 
 
Beste professor Cremers, als tweede promotor heeft ook u ieder stuk uit dit 
proefschrift onder ogen gehad voordat het werd gepubliceerd. Echt bijzonder 
hoe snel u altijd weer reageerde met goede tips, bedankt hiervoor. De data van 
diverse artikelen zijn ook mede aan u te danken; u heeft vele patiënten die ik in 
dit proefschrift beschrijf geopereerd. 
 
Beste dr. Mylanus, beste Emmanuel, ook jij bent een belangrijke drijfveer 
geweest achter mijn onderzoek. We begonnen samen aan de start van de multi-
centre trial voor EAS, wat toen nog onderdeel van mijn proefschrift leek te 
worden. Uiteindelijk heeft mijn promotietraject toch een hele andere wending 
gekregen. Je goede ideeën wist je met veel enthousiasme op me over te 
brengen. Ik heb er bewondering voor hoe je je klinische en wetenschappelijke 
activiteiten weet te combineren.  
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Beste dr. Mulder, beste Jef, als operateur ben je echt een voorbeeld voor me. 
Ook jij hebt een deel van de operaties, beschreven in dit proefschrift, verricht. 
Tijdens besprekingen ben je altijd kritisch, dit is enorm leerzaam. 
 
Beste leden van de manuscriptcommissie, bedankt voor de snelle beoordeling 
van dit proefschrift. Hierdoor is het mogelijk geworden voor mij om te 
promoveren voor aanvang van mijn zwangerschapsverlof.       
 
Beste John Noten, beste Bart Luijten, jullie hebben de uitgebreide ASSR 
metingen verricht, die beschreven zijn in hoofdstuk 3.1. Bedankt hiervoor. 
 
Beste Carine Hendriks, of ik nu op zoek was naar Ad, op zoek was naar een 
status of een afspraak wilde inplannen voor een van de patiënten van mijn 
onderzoek, altijd hielp je me weer, bedankt. 
 
Beste Renee Clapham, bedankt voor je snelle correcties van mijn stukken. Ik kon 
je hulp goed gebruiken, aangezien mijn talenknobbel me regelmatig in de steek 
laat. 
 
Beste Wendy, voor de finishing touch wil ik je enorm bedanken. Je hebt een 
hoop werk verzet in korte tijd. Het is hartstikke mooi geworden. 
 
Zonder goede sfeer op het werk en collegialiteit was dit proefschrift ook nooit 
tot stand gekomen. Daar ben ik jullie, lieve collega’s en oud-collega’s, arts-
assistenten van de KNO in het Radboud, dan ook erg dankbaar voor. Ik ben erg 
blij dat de sfeer onderling zo goed is, zowel binnen als buiten het ziekenhuis. 
 
 
Dankwoord 
 
 
 
 167 
Prof. Graamans en prof. Marres, jullie wil ik nogmaals bedanken voor het feit 
dat jullie me hebben aangenomen binnen de afdeling KNO. Het heeft heel wat 
telefoontjes vanuit vakantie in Zuid-Afrika gekost, maar na het verlossende 
telefoontje bij terugkomst op Schiphol was de vreugde dan ook extra groot. 
Sowieso was dat het echte begin van dit proefschrift. Maar naast het onderzoek 
is het belangrijkste dan toch de opleiding tot KNO-arts. Ik heb het enorm naar 
mijn zin binnen dit fantastische vakgebied en ben alle stafleden en perifere 
opleiders in het CWZ en in VieCuri Venlo-Venray dan ook erg dankbaar voor de 
goede begeleiding. 
 
Willemijn, paranimf, jij weet als geen ander hoe het is om onderzoek te doen 
naast je opleiding tot medisch specialist. Ik heb je leren kennen tijdens de 
introductietijd van onze studie geneeskunde en daar ben ik erg blij mee. Ik vind 
onze vriendschap zeer waardevol en vind het dan ook geweldig dat je mijn 
paranimf wilt zijn.      
 
Beatrix, mijn andere paranimf. Jacqueline en jij zijn mijn twee zusjes. Ik ben 
erg blij met de band die we hebben en eigenlijk altijd hebben gehad. We delen 
alles met elkaar, hebben dezelfde interesses en kunnen altijd op elkaar 
terugvallen. Lieve mama, jij bent daar toch wel een grote oorzaak van. Met de 
opvoeding die jij ons hebt gegeven ben ik heel erg blij, ik ga dat later precies 
zo proberen te doen. Ik kan met alles bij je terecht, super fijn! 
 
Lieve Twan, tenslotte nog een woord van dank aan jou, gewoon om wie je bent. 
We hebben het zo fijn samen. Op naar een nieuwe fase: papa en mama worden! 
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